RESEARCH



Nebulized dexmedetomidine for attenuating hemodynamic response to laryngoscopy and endotracheal intubation in adult patients undergoing surgeries under general anaesthesia: a systematic review and meta-analysis of randomized controlled trials

Mayank Gupta^{1*}, Rachna Rohilla², Priyanka Gupta³, Hemanthkumar Tamilchelvan¹, Udita Joshi⁴ and Jyoti Kanwat¹

Abstract

Background Sympathetic stimulation associated with laryngoscopy and endotracheal intubation (ETI) may lead to adverse cardio-/cerebro-vascular events in susceptible patients. Nebulization is a novel route for dexmedetomidine administration providing a large surface area for absorption while avoiding bradycardia and hypotension associated with intravenous route. We aimed to evaluate the efficacy and safety of dexmedetomidine nebulization for attenuating hemodynamic response to ETI in adult patients undergoing surgery under general anaesthesia.

Methods This systematic review was registered prospectively in the International Prospective Register of Systematic Reviews (CRD42023403624). PubMed, Embase (OvidSP), Cochrane library, Scopus (Elsevier), Web of Science (Clarivate) and Google Scholar were systematically searched from database inception until March 31, 2023. Two reviewers independently screened titles, abstracts and then full text against pre-specified eligibility criteria. Randomized controlled trials (RCTs) assessing effect of dexmedetomidine nebulization on hemodynamic response to ETI in adult patients undergoing surgeries under general anaesthesia were included. All studies reporting heart rate and systolic blood pressure at baseline and various time points after ETI were included. A pre-piloted data extraction form, Cochrane revised risk-of-bias tool (ROB 2) tool, GRADE approach and RevMan 5.4.1 (Cochrane Collaboration, Copenhagen, Denmark) were used for data extraction, risk of bias assessment, rating certainty of evidence and data synthesis respectively. Mean difference and relative risk with 95% Confidence Interval (CI) were used for continuous and dichotomous variables respectively.

*Correspondence: Mayank Gupta drm_gupta@yahoo.co.in Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.gr/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.gr/licenses/by/4.0/. The Creative Commons Public Domain Dedicated in a credit line to the data.

Results Six RCTs randomized 480 patients with ASA I/II patients aged < 60 years of age and undergoing elective surgeries to receive either dexmedetomidine (n = 240) or saline nebulization (n = 240). Except for one RCT which used 2 µg/kg, all other RCTs used dexmedetomidine dose of 1 µg /kg. Heart rate, systolic, diastolic and mean blood pressure were significantly lower in the dexmedetomidine group at all the measured time points after laryngoscopy and ETI with the only exception being systolic blood pressure at 3 min [mean difference -13.86 (95% CI -30.01 to 2.99), p = 0.09]. Bradycardia and hypotension as adverse effects were absent across the included studies. However, only one-third of the included studies had a low risk of bias and strength of evidence was very low according to the GRADE assessment.

Conclusions Compared to placebo, premedication with dexmedetomidine nebulization was associated with lower HR and BP following ETI without any risk of bradycardia and hypotension. However, the strength of evidence was very poor and came from just one country. Future well designed and conducted studies in different populations are warranted.

Trial registration PROSPERO Registration number: CRD42023403624

Keywords Dexmedetomidine, Endo-tracheal intubation, Laryngoscopy, Meta-analysis, Systematic review, Hemodynamic response, Stress response

Background

Laryngoscopy and endotracheal intubation (ETI) are associated with sympathetic stimulation induced hemodynamic changes [1]. The consequent increase in heart rate (HR) and blood pressure (BP) though short-lived may lead to myocardial infarction, cardiac arrhythmias, cardiac failure and cerebrovascular accidents in patients with underlying cardiovascular or cerebrovascular diseases [1]. Premedication with various agents has been shown to attenuate this sympathetic response and its associated risk of arrhythmias and myocardial infarction [1]. However, none of them is ideal and each of them is associated with its unique adverse effects like hypotension, bradycardia, chest rigidity or increased bronchomotor tone [1].

Dexmedetomidine is a centrally acting α -2 adrenergic agonist with sedative, hypnotic, analgesic, anxiolytic, antisialagogue, antinociceptive and sympatholytic action [2, 3]. Premedication with dexmedetomidine through intravenous, intramuscular and intranasal route has been shown to effectively attenuate hemodynamic response to laryngoscopy and ETI [4-10]. However, its use is associated with adverse effects like hypotension and bradycardia with intravenous route and nasal irritation with intranasal route [5-8, 11]. A 2021 systematic review and meta-analysis (SRMA) showed intravenous dexmedetomidine to significantly attenuate tracheal intubation associated increase in HR and BP but associated with significant risk of bradycardia and hypotension; recommending cautious evaluation while using it in daily practice [4].

Nebulization provides an alternative route of dexmedetomidine premedication with high bioavailability through both nasal (65%) and oral mucosa (82%) and avoid a venipuncture as a prerequisite. Recent studies have shown nebulisation as a novel route of dexmedetomidine administration for attenuation of hemodynamic response to ETI [12–14]. However, no current or planned systematic review evaluating the safety and efficacy of nebulized dexmedetomidine for blunting hemodynamic response to laryngoscopy and ETI in adult patients was identified.

Therefore, the present SRMA was conducted to systematically identify, collate, critically appraise and synthesize available evidence on dexmedetomidine nebulisation for attenuating hemodynamic response to laryngoscopy and ETI in adult patients (\geq 18 years) undergoing surgery under general anaesthesia. Our findings will help clinicians in evidence based decision-making and formulation of institutional guidelines.

Methods

This systematic review has been reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) 2020 standards [15]. The protocol for this systematic review was registered prospectively in the International Prospective Register of Systematic Reviews (PROSPERO No. CRD42023403624).

Search strategy

A preliminary search helped in identifying thesaurus and free text terms for the key concepts (laryngoscopy, endotracheal intubation and dexmedetomidine). The thesaurus and free text terms for a similar concept were combined using Boolean operator "OR". The search strings for different concepts were then combined using Boolean operator "AND". A systematic and comprehensive literature search was performed in the following electronic bibliographic databases: PubMed, Embase and Embase Classic (OvidSP), Cochrane library (https://www.cochr anelibrary.com), Scopus (Elsevier), Web of Science (Clarivate) and Google Scholar from inception to 31st March 2023. The search strategy was limited to randomized controlled trials (RCTs) conducted in humans and published in English language. No date or age restrictions were applied. The search strategy was first formulated for Embase and later adapted for other databases. The search strategy and literature searches were formulated and conducted by one reviewer (MG) and re-ran by another experienced reviewer (UJ) to rule out syntax or any other error. The search strings for all the databases as they were run has been reported in the Supplementary file 1.

To ensure literature saturation, reference lists of included articles and relevant systematic reviews were screened and citation tracking of included articles (on Google scholar and Scopus) was done to identify any additional relevant article. Screening of reference lists and citation tracking continued until no new articles were identified.

Study selection

PICOS format helped operationalise the review question into key inclusion and exclusion criteria. RCTs comparing preoperative administration of dexmedetomidine nebulization with either placebo or no intervention for attenuating hemodynamic response (as measured by HR and BP at any time point up to 10 min after ETI) to laryngoscopy and ETI in adult patients (≥18 years of age) undergoing surgery under general anaesthesia with ETI were included. Studies evaluating dexmedetomidine nebulization in pediatric patients, adult patients undergoing tracheal intubation other than for surgery or dexmedetomidine administration through any other route were excluded. Non-randomized studies and evidence synthesis were not included, however, their reference lists were screened to identify any eligible study missed through database searching.

Studies identified through database search were transferred to EndNote reference manager software (V.20, Clarivate Analytics, Philadelphia, Pennsylvania, USA) for de-duplication. De-duplicated results were transferred to Rayyan (www.rayyan.ai) in which two reviewers (MG, HT) independently performed title and abstract screening against the pre-defined inclusion and exclusion criteria (Table 1). Full texts of potentially eligible studies and studies where eligibility could not be determined from title/abstract screening were retrieved and screened independently by two reviewers (MG, HT) for inclusion. Any discrepancies were resolved through discussion and arbitrated by a third reviewer (PG) where necessary. An audit trail of all the disagreements, reasons for the same and resolutions made ensured trustworthiness of the process.

Outcome measures

The primary outcome measures analyzed were heart rate (HR) and systolic blood pressure (SBP) at baseline and at any time point till 10 min after ETI (as provided in the published report). Other additional outcomes included diastolic (DBP) and mean (MBP) blood pressure at any time point till 10 min after ETI. We also collected data on bradycardia (% of patients), hypotension (% of patients) and postoperative nausea (% of patients), vomiting (% of patients), respiratory depression (% of patients) or any other adverse outcome as reported in the study.

Data extraction

Two reviewers (MG and RR) independently extracted following data from included studies on a pre-piloted data extraction excel form designed specifically for this review: first author, publication year, inclusion and exclusion criteria, details of intervention and control group (dose, mode of nebulisation, duration of administration), number and demographic characteristics of participants in each group, surgical procedures, rate and reasons for dropout and outcome parameters. Following outcome parameters were retrieved: HR, SBP, DBP and MBP at baseline and at all time till 10 min (as provided in the published report) after ETI; drugs used at induction of anaesthesia and their doses, intraoperative bradycardia or hypotension (% patients) and postoperative nausea and vomiting (% patients). Corresponding authors of included studies were contacted through e-mail for any missing data. Any discrepancies between the reviewers in the extracted data were resolved through discussion.

Risk of bias assessment and rating certainty of evidence

Two reviewers (MG and RR) independently assessed each included study for risk of bias using Cochrane revised risk-of-bias tool for randomized trials (RoB 2) [21, 22]. RoB-2 assessment was done using the RoB Excel Tool (https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2). The tool assesses each study for risk of bias on five domains: risk of bias arising from the randomization process, bias arising due to deviations from the intended interventions, bias arising due to missing outcome data, bias in measurement of outcome and bias in selection of the reported result. Each domain in individual studies was graded as "low risk of bias", "some concerns" or "high risk of bias" for each included study graded across all domains [21]. The overall risk of bias for individual studies was determined by highest RoB level in any domain. Any discrepancies were resolved by discussion and arbitrated by a third reviewer (PG) where necessary.

Author Vear	Donled age	(N) selet	Malas (N) Intervention		Control	2	Induction regimen	Basults		
	(Mean + SD)					=				
			Dexmed	z	Placebo	z		Hemodynamic	Adverse effects	Other
Hussain 2019, India [16]	34.5±5.2 3	۳. ۲	Dexmed 2 µg /kg in 5 ml NS 30 min before induction and laryngoscopy	35 5	5 ml NS	35 ₹ ≪ Pr	Fentanyl 2 µg /kg, Propofol 2 mg/kg, Vecuronium 0.1 mg/ kg IV	Control group had statistically higher values of HR, SBP, DBP, MAP after intubation at all time intervals compared to dexme- detomidine group.	No adverse event reported in either group	
Misra 2021, India [12]	39.15±11.25	72	Dexmed 1 µg /kg in 3–4 ml NS 30 min before induction and laryngoscopy	e 09	3-4 ml NS	0 2 H 2 2 0	Ondansetron 4 mg, Midazolam 1 mg, Fentanyl 2 µg g/ kg, propofol 10 mg boluses, vecuronium 0.15 mg/kg lV	After laryngoscopy and intubation, a significant trend of decrease in HR in dexmedetomidine group versus control group at all time points. No difference in SBP response between two groups.	Post-operative nausea and vomit- ing in 3/57 patients in dexmedetomidine group and 1/59 in normal saline group.	Induction dose of propofol, intraopera- tive fentanyl consump- tion and mean iso- flurane requirements were significently were significently ine group versus con- trol group.
Sheth 2021, India [17]	29±7.52	27	Dexmed 1 µg /kg in 5 ml NS 10 min before shifting to OT	25 5	s mi Ns	P P F F F F F F F F F F F F F F F F F F	Glycopyrrolate 0.005 mg/kg IM, Fentanyl 2 µg/kg, Propofol 2 -2.5 mg/kg, atracurium 0.5 mg/ kg IV	There was sig- nificantly reduced SBP, DBP, MAP at 1, 5 and 10 min after laryngoscopy and intubation in dexmedetomidine compared to control group. No difference between the two groups in terms of HR response.	No adverse event reported in either group	
Suryawanshi 2022, India [18]	43.41 ± 13.21	Ē	Dexmed 1 µg /kg in 3–4 ml NS 30 min before induction and laryngoscopy	30	3-4 ml NS	8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	Glycopyrrolate 0.004 mg/kg IV, Inj. Midazolam 0.02 mg/ kg IV and Inj. Fen- tanyl 1- 2 µg /kg IV, propofol 2 mg/kg, Succinylcholine 2 µg/ kg IV	HR, SBP, DBP, MAP significantly lower in dexmedeto- midine group at all time points studied as compared to the control group.	No adverse event reported in either group	Lower post-operative sore throat in dexme- detomidine group.
Shrivastava 2022, India [19]	38.97±14.19	28	Dexmed 1 µg /kg in 5 ml NS 30 min before induction and laryngoscopy	505	5 ml NS	So A A A A A A A A A A A A A A A A A A A	Alprazolam 0.5 mg Midazolam 1 mg, Fentanyl 2 µg/kg, propofol 1–2 mg/kg, kg IV	SBP, DBP, MAP and HR significantly lower in dexmedetomidine group compared to control group at 1, 5, 10 min.	No adverse event reported in either group	Nebulised dexmedeto- midine has a dose spar- ing effect on induction dose of propofol.

Table 1 Characteristics of RCTs included in meta-analysis

Author Year,	Pooled age	Males (N)	Males (N) Intervention	0	Control	Induction regimen Results	Results		
country	(Mean±s∪)		Dexmed	z	N Placebo N		Hemodynamic	Adverse effects	Other
Kaila 2023, India [20] 35.43 ± 7.97	35.43 ± 7.97	43	Dexmed 1 µg/kg in 3-4 ml NS 30 min before induction and laryngoscopy	40 3	-4 ml NS 40	 40 3–4 ml NS 40 Metoclopramide 10 mg IV, Ondanse- tron 8 mg, Fentanyl 1–2 µg/kg, Propofol 2 mg/kg, Succinyl- choline 100 µg IV 	SBP, DBP, MAP signifi- No adverse cantly lower in dex- event repor medetomidine group in either grc compared to control group at 2,4,6,8 min.	No adverse event reported in either group	

Table 1 (continued)

HR Heart Rate, DBP Diastolic Blood Pressure, IV Intravenous, Kg Kilogram, MBP Mean Blood Pressure, mg Milligram, µg Microgram, SBP Systolic Blood Pressure

Two authors (MG and RR) independently rated the certainty of evidence according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) working group system using the GRADEpro software (https://www.gradepro.org). The quality of evidence was downgraded depending upon the degree of bias, inconsistency, indirectness and imprecision. Any disagreements were resolved through consultation and arbitrated by a third author if required (PG).

Statistical analysis

We performed inverse variance random-effect meta-analvsis using RevMan 5.4.1 [Review Manager Version 5.4.1, The Cochrane Collaboration, 2020]. HR, SBP, DBP and MBP were treated as continuous variables and incidence of adverse effects (bradycardia, hypotension) as dichotomous variables. Continuous outcomes were reported as weighted mean difference with 95% Confidence Interval (CI). Significance was set at P < 0.05. Outcome heterogeneity between the studies was assessed using Cochran's Q test and quantified with I-square statistic. I-square > 50% was considered as statistically significant heterogeneity between the studies. Sensitivity analysis was performed by removing studies using different doses of nebulized dexmedetomidine and observing its effect on outcome heterogeneity and effect estimate. Subgroup analysis was performed if there were more than equal to three studies using different doses of nebulized dexmedetomidine.

Results

Search results

Database search identified 1412 records after excluding 1082 duplicates. Forty-nine reports underwent fulltext screening after removing 1363 records during title and abstract screening. No new articles were identified through reference list screening and citation tracking. We excluded 43 reports for reasons cited in PRISMA flow diagram created using Shinny app (Fig. 1) [23]. A total of seven studies were selected [12, 13, 16-20]. However, Kumar et al. did not mention effect on HR which was the primary outcome of the study and data for BP (SBP, DBP and MBP) was provided only in graphical figures in the article from which the exact mean (SD) values at each time point could not be extracted for meta-analysis [13]. The data could not be obtained despite email request and hence the study was excluded from the data-synthesis [13]. A total of six randomized controlled trials underwent quality appraisal and data synthesis [12, 16-20].

Study characteristics

Six studies randomized 480 American society of Anaesthesiologist (ASA) I and/or II patients, <60 years of age undergoing elective surgeries into intervention (n=240)and control group (n=240) [12, 16–20]. The dose of dexmedetomidine used was 1 mcg/kg in all except one study which used 2mcg/kg (Table 1). All used normal saline as placebo in the control group. The main source of clinical heterogeneity was due to the anaesthesia regimen (Table 1). All reported stress response to endotracheal intubation as the primary outcome. However, only three studies reported sample size calculation [12, 17, 19]. The primary outcome of the studies were effect on HR, SBP and secondary outcomes were effect on DBP, MAP and safety analysis.

Synthesis of results

All the six studies mentioned above were included in the meta-analysis for primary outcome using random effect model. The data on each time point was not provided by all the studies included. So the analysis for each time point included those studies which provided data for that time point.

Primary outcomes

Effect on heart rate (HR) The nebulized dexmedetomidine significantly reduced the mean HR as compared to the control group at all measured time points [mean difference -8.59 (95% CI -16.42 to -0.75), p = 0.03, $I^2 = 92\%$ at 1 min (Fig. 2a); mean difference -13.48 (95% CI -21.03 to -5.94), p = 0.0005, $I^2 = 90\%$ at 2 min (Fig. 2b); mean difference -14.71 (95% CI -25.40 to -4.01); p = 0.007, $I^2 = 91\%$ at 3 min (Fig. 2c); mean difference -10.98 (95% CI -17.25 to -4.72), p = 0.0006, $I^2 = 88\%$ at 4 min (Fig. 2d); mean difference -7.16 (95% CI -12.49 to -1.83), p = 0.008, $I^2 = 85\%$ at 5 min (Fig. 2e); mean difference -11.85 (95% CI -14.62 to -9.09), p < 0.00001, $I^2 = 26\%$ at 6 min (Fig. 2f); mean difference -10.97 (95% CI -17.04 to -4.91), p=0.0004, $I^2 = 84\%$ at 8 min (Fig. 2g) and mean difference -7.46 (95%) CI -13.02 to -1.90), p = 0.009, $I^2 = 88\%$ at 10 min (Fig. 2h)] of endotracheal intubation. However there was high heterogeneity in the studies included with $I^2 > 84\%$ at all the time points, except at 6 min where heterogeneity was 26%.

Effect of on SBP The nebulized dexmedetomidine significantly reduced the mean SBP as compared to normal saline at all measured timepoints [mean difference -12.48 (95% CI -19.85 to -5.10), p=0.0009, I²=84% at 1 min (Fig. 3a); mean difference -21.00 (95% CI -30.41 to -11.60), p < 0.0001, I²=88% at 2 min (Fig. 3b); mean difference -13.89 (95% CI -24.33 to -3.45), p=0.009, I²=94% minute at 4 min (Fig. 3d); mean difference -9.25 (95% CI -14.99 to -3.51), p=0.002, I²=85% at 5 min (Fig. 3e); mean difference -10.82 (95% CI -19.74 to -1.89), p=0.02,




Fig. 1 PRISMA flow diagram

 I^2 = 88% at 6 min (Fig. 3f); mean difference -7.56 (95% CI -11.88 to -3.23), *p*=0.0006, I^2 = 48% at 8 min (Fig. 3g); and mean difference -5.23 (95% CI -7.47 to -2.99), *p* < 0.00001, I^2 = 0% at 10 min (Fig. 3h)] after endotracheal intubation, except at 3 min after intubation where although overall reduction in SBP was observed with nebulized dexmedetomidine as compared to nebulized normal saline but was not statistically significant [mean difference -13.86 (95% CI -30.01 to 2.99), *p*=0.09, I^2 = 94%] as the overall effect 95% CI crosses the line of no difference (Fig. 3c).

Secondary outcomes

The secondary end point was effect of nebulized dexmedetomidine on DBP and MAP as compared to nebulized normal saline at various end points.

Effect on DBP The nebulized dexmedetomidine as compared to normal saline significantly reduced the mean DBP at 1 min after endotracheal intubation and the reduction in DBP persisted till 10 min [mean difference -9.78 (95% CI -16.23 to -3.32), p=0.003, I² of 91% at 1 min; mean difference -14.73 (95% CI -22.30 to -7.15), p=0.0001, I²=89% at 2 min; mean difference -8.87 (95%

CI -10.59 to -7.15), p < 0.00001, $I^2 = 88\%$ at 5 min; mean difference -4.88 (95% CI -6.62 to -3.13), p < 0.00001, $I^2 = 0\%$ at 10 min post-intubation]. The forest plots are available as Fig. 4.

Effect on MBP Just like DBP, the significant reduction in MBP was seen in nebulized dexmedetomidine group as compared to normal saline group at all the measured time points after endotracheal intubation from 1 min till 10 min [mean difference -10.47 (95% CI -17.66 to -3.28), p=0.004, I² of 91% at 1 min; mean difference -15.54 (95% CI -24.88 to -6.19), p=0.001, I²=93% at 2 min; mean difference -8.26 (95% CI -14.05 to -2.47), p=0.005, I²=89% at 5 min; mean difference -4.13 (95% CI -5.99 to -2.27), p<0.0001, I²=0% at 10 min] post-intubation. The forest plots are available as Fig. 5.

Safety assessment The included studies did not report any adverse effects like intraoperative bradycardia or hypotension with use of nebulized dexmedetomidine, unlike intravenous dexmedetomidine during intubation. Post-operative nausea and vomiting was reported by only one study, Misra et al. in 3/57 patients (5.26%) in dexmedetomidine group and 1/59 (1.69%) in normal saline group (Table 1).

		Nah Davmada	a midin a	Neb Ne	man l Ca	line		Maan Difference	Neen Difference	
	Study or Subgroup	Neb Dexmeder Mean S	D Total	Neb No Mean	rmal Sa SD		Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% Cl	
	Hussain et al	86.47 13.4			12.22	35	19.5%	-7.70 [-13.72, -1.68]		
a) Effect on HR at 1 minute	Misra et al	84.53 13.4	1 60	93.46		60	18.3%	-8.93 [-16.50, -1.36]	-	I
a) Encer on fine at 1 minute	Sheth et al	106.8 6.3		105.68	7.78	25	20.9%	1.12 [-2.81, 5.05]	+	I
	Shrivastava et al Suryawanshi et al	83.34 12.3 85.3 8.9		91.94 104.1	5.89	50 30	20.4%	-8.60 [-13.42, -3.78] -18.80 [-22.64, -14.96]		I
	Jui famansin et al	03.5 0.2	<i>i</i> u <i>b</i> u	104.1	5.05	30	20.07	-10.00 [-11.04]		I
	Total (95% CI)		200				100.0%	-8.59 [-16.42, -0.75]	•	
	Heterogeneity: Tau ² =			(P < 0.00	001); P	= 92%			-100 -50 0 50	100
	Test for overall effect:	z = 2.15 (P = 0.15)	03)						Favours [experimental] Favours [control]	
		Neb Dexmede	tomidine	Neb No	rmal Sa	line		Mean Difference	Mean Difference	=
	Study or Subgroup		D Total	Mean	SD		Weight	IV, Random, 95% CI	IV, Random, 95% CI	
b) Effect on HR at 2 minute	Hussain et al	88.65 13.4		98.11		35	24.1%	-9.46 [-15.23, -3.69]	-	
by Effect of The at 2 minute	Kalla et al	76.08 5.8		89.11		40	26.1%	-13.03 [-16.93, -9.13]	+	
	Misra et al Suryawanshi et al	82.12 15.5 84.36 8.6		88.96 108.03	16.63	60 30	23.6%	-6.84 [-13.02, -0.66] -23.67 [-27.60, -19.74]		I
	Juryamansin et ar	04.30 0.0	30	100.05	0.72	30	20.14	-23.07 [-27.00, -15.74]	-	
	Total (95% CI)		165				100.0%	-13.48 [-21.03, -5.94]	•	
	Heterogeneity: Tau ² =			{P < 0.00)001); P	= 90%			-100 -50 0 50	100
	Test for overall effect:	Z = 3.50 (P = 0.)	0005}						Favours [experimental] Favours [control]	
		Neb Dexmede	tomidine	Neb No	rmal Sa	line		Mean Difference	Mean Difference	=
a) Effect on UD at 2 minute	Study or Subgroup		D Total	Mean	SD		Weight	IV, Random, 95% CI	IV, Random, 95% CI	
c) Effect on HR at 3 minute	Hussain et al	86.54 13.5	51 35	98.4	10.23	35	33.3%	-11.86 [-17.47, -6.25]	+	
	Misra et al	79.53 13		86.74	23.1	60	31.9%	-7.21 [-14.02, -0.40]	=-	I
	Suryawanshi et al	83.56 8.3	75 30	107.86	7.14	30	34.6%	-24.30 [-28.34, -20.26]		
	Total (95% CI)		125			125	100.0%	-14.71 [-25.40, -4.01]	•	
	Heterogeneity: Tau ² =			(P < 0.00	001); r	- 91%			-100 -50 0 50	100
	Test for overall effect:	Z = 2.70 (P = 0.)	007)						Favours [experimental] Favours [control]	100
										=
	Study or Subgroup	Neb Dexmede Mean S	tomidine D Total	Neb No Mean	rmal Sa SD		Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% Cl	
d) Effect on HR at 4 minute	Hussain et al	86.45 13.4		93.25		35	23.3%	-6.80 [-12.38, -1.22]		
	Kalla et al	74.08 4.1		87.55		40	26.3%	-13.47 [-16.95, -9.99]	-	I
	Misra et al	78.36 11.4		82.74		60	24.8%	-4.38 [-8.93, 0.17]	-	I
	Suryawanshi et al	83.4 8.5	59 30	102.06	7.27	30	25.6%	-18.66 [-22.69, -14.63]	*	
	Total (95% CI)		165			165	100.0%	-10.98 [-17.25, -4.72]	•	I
	Heterogeneity: Tau ² =			(P < 0.00	01); l ² -	88%			-100 -50 0 50	100
	Test for overall effect:	Z = 3.44 (P = 0.)	0006)						Favours [experimental] Favours [control]	100
	ļ									
			tomidine	Neh N	ormal S:	aline		Mean Difference	Mean Difference	
	Study or Subgroup	Neb Dexmede Mean	tomidine SD Total		ormal Sa SD		Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% Cl	
	Study or Subgroup Hussain et al	Mean 84.48 13	SD Total	Mean 91.22	SD 9.89	Total 35	19.0%	IV, Random, 95% CI -6.74 [-12.28, -1.20]		
	Hussain et al Misra et al	Mean 84.48 13 75.96 13.	SD Total 3.5 35 41 60	Mean 91.22 83.6	5D 9.89 19.14	Tota 35 60	19.0% 18.5%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73]		
e) Effect on HR at 5 minute	Hussain et al Misra et al Sheth et al	Mean 84.48 13 75.96 13. 104.16 5.	SD Total 3.5 35 41 60 44 25	Mean 91.22 83.6 104.12	SD 9.89 19.14 7.5	Total 35 60 25	19.0× 18.5× 21.5×	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67]		
e) Effect on HR at 5 minute	Hussain et al Misra et al	Mean 84.48 13 75.96 13. 104.16 5. 81.56 13.	SD Total 3.5 35 41 60 44 25	Mean 91.22 83.6 104.12 89.56	SD 9.89 19.14 7.5	Tota 35 60	19.0× 18.5× 21.5× 19.6×	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67]		
e) Effect on HR at 5 minute	Hussain et al Misra et al Sheth et al Shrivastava et al Suryawanshi et al	Mean 84.48 13 75.96 13. 104.16 5. 81.56 13.	SD Total 3.5 35 41 60 44 25 33 50 54 30	Mean 91.22 83.6 104.12 89.56 96.63	SD 9.89 19.14 7.5 12.59	Total 35 60 25 50 30	19.0% 18.5% 21.5% 19.6% 21.3%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.83]		
e) Effect on HR at 5 minute	Hussain et al Misra et al Sheth et al Shrivastava et al Suryawanshi et al Total (95% CI)	Mean 84.48 13 75.96 13. 104.16 5. 81.56 13. 83 8.	SD Total 3.5 35 41 60 44 25 33 50 54 30 200	Mean 91.22 83.6 104.12 89.56 96.63	SD 9.89 19.14 7.5 12.59 6.3	Total 35 60 25 50 30 200	19.0× 18.5× 21.5× 19.6×	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.83]	IV, Random, 95% Cl	
e) Effect on HR at 5 minute	Hussain et al Misra et al Sheth et al Shrivastava et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² =	Mean 84.48 12 75.96 13. 104.16 5. 81.56 13. 83 8. 30.90; Chr ² = 2 2	SD Total 3.5 35 41 60 44 25 33 50 54 30 200 6.33, df = 4	Mean 91.22 83.6 104.12 89.56 96.63	SD 9.89 19.14 7.5 12.59 6.3	Total 35 60 25 50 30 200	19.0% 18.5% 21.5% 19.6% 21.3%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.83]	IV, Random, 95% CI	100 ^l
e) Effect on HR at 5 minute	Hussain et al Misra et al Sheth et al Shrivastava et al Suryawanshi et al Total (95% CI)	Mean 84.48 12 75.96 13. 104.16 5. 81.56 13. 83 8. 30.90; Chr ² = 2 2	SD Total 3.5 35 41 60 44 25 33 50 54 30 200 6.33, df = 4	Mean 91.22 83.6 104.12 89.56 96.63	SD 9.89 19.14 7.5 12.59 6.3	Total 35 60 25 50 30 200	19.0% 18.5% 21.5% 19.6% 21.3%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.83]	IV, Random, 95% CI	100 ⁱ
e) Effect on HR at 5 minute	Hussain et al Misra et al Sherh et al Shrhvastava et al Suryawanshi et al Total (95% Cl) Heterogenethy: Tau ² = Test for overall effect:	Mean 84.48 13 75.96 13. 104.16 5. 81.56 13. 83 8. 30.90; Ch ² = 2 Z = 2.63 (P = 0 Neb Dexmede	SD Total 3.5 35 41 60 44 25 33 50 54 30 200 200 (6.33, df = 4) 008) etomidine 100	Mean 91.22 83.6 104.12 89.56 96.63	SD 9.89 19.14 7.5 12.59 6.3 001); t ²	Total 35 60 25 50 30 200 = 85%	19.0% 18.5% 21.5% 19.6% 21.3%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.83] -7.16 [-12.49, -1.83] Mean Difference	IV, Random, 95% CI	100'
e) Effect on HR at 5 minute	Hussain et al Misra et al Sherh et al Shrivastava et al Suryawanshi et al Total (95% Cl) Heterogenetly: Tau ² = Test for overall effect: Study or Subgroup	Mean 84.48 13 75.96 13 104.16 5 81.56 13 83 8 30.90; Ch ² = 2 Z = 2.63 (P = 0 Neb Dexmede Mean	SD Total 3.5 35 41 60 44 25 33 50 54 30 200 200 :6.33, df = 4 :008} ttomidine SD Total	Mean 91.22 83.6 104.12 89.56 96.63 4 (P < 0.0 Neb No Mean	SD 9.89 19.14 7.5 12.59 6.3 001); ² ormal Sa SD	Total 35 60 25 50 30 200 - 85% line Total	19.0% 18.5% 21.5% 19.6% 21.3% 100.0% Weight	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI	IV, Random, 95% CI	100
e) Effect on HR at 5 minute f) Effect on HR at 6 minute	Hussain et al Misra et al Sheth et al Shrhwastava et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² – Test for overall effect: Study or Subgroup Kalla et al	Mean 84.48 12 75.96 13. 104.16 5. 81.56 13. 83 8. 30.90; Ch² = 2 2 Z = 2.63 (P = 0 Neb Dexmede Mean 74.2 5.	SD Total 3.5 35 41 60 44 25 33 50 54 30 200 200 :6.33, df = 4 .008) ttomidine SD SD Total 37 40	Mean 91.22 83.6 104.12 89.56 96.63 4 (P < 0.0 Neb No Mean 87.82	SD 9.89 19.14 7.5 12.59 6.3 001); P ormal Sa SD 8.84	Total 35 60 25 50 30 200 - 85%	19.0% 18.5% 21.5% 19.6% 21.3% 100.0% Weight 46.6%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.83, -10.41]	IV, Random, 95% CI	100
	Hussain et al Misra et al Sherh et al Shrivastava et al Suryawanshi et al Total (95% Cl) Heterogenetly: Tau ² = Test for overall effect: Study or Subgroup	Mean 84.48 12 75.96 13. 104.16 5. 15.56 13. 83 8. 30.90; Chi ² = 2 2 2 Z = 2.63 (P = 0 Neb Dexmede Mean 74.97 12	SD Total 3.5 35 41 60 44 25 33 50 54 30 200 200 :6.33, df = 4 :008} ttomidine SD Total	Mean 91.22 83.6 104.12 89.56 96.63 4 (P < 0.0 Neb No Mean 87.82 82.94	SD 9.89 19.14 7.5 12.59 6.3 001); ² ormal Sa SD	Total 35 60 25 50 30 200 - 85% line Total	19.0% 18.5% 21.5% 19.6% 21.3% 100.0% Weight	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI	IV, Random, 95% CI	100
	Hussain et al Misra et al Sherh et al Shrhvastava et al Suryawanshi et al Total (95% Cl) Heterogenethy: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Suryawanshi et al	Mean 84.48 11 75.96 13. 104.16 5. 81.56 13. 83 8. 30.90; Chi ² = 2 2 2.63 (P = 0) 0 Neb Dexmeder Mean 74.97 12	SD Total 3.5 35 41 60 44 25 33 50 54 30 200 200 66.33, df = 4 .008) itomidine SD SD Total 37 40 2.4 60 3.4 30	Mean 91.22 83.6 104.12 89.56 96.63 • (P < 0.0 Neb No Mean 87.82 82.94 94.06	SD 9.89 19.14 7.5 12.59 6.3 001); f ² 0001); f ² 8.84 21	Total 35 60 25 50 30 200 = 85% Iline Total 40 60 30	19.0% 18.5% 21.5% 19.6% 21.3% 100.0% Weight 46.6% 17.3% 36.1%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.83, -10.41] -7.97 [-1.41, 4.1.80] -11.43 [-15.30, -7.56]	IV, Random, 95% CI	100
	Hussain et al Misra et al Sheth et al Shrkhastava et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² – Test for overall effect: Study or Subgroup Kalla et al Misra et al Total (95% Cl)	Mean 84.48 12 75.96 13. 104.16 5. 81.56 13. 83 8. 30.90; Ch² = 2 2.63 (₱ = 0 Neb Dexmede Mean 74.2 5. 74.2 5. 82.63 8	SD Total 3.5 35 41 60 44 25 33 50 54 30 200 200 :6.33, df = 4 :008) 37 :07 400 :4.4 60 :4.4 30 130 130	Mean 91.22 83.6 104.12 89.56 96.63 4 (P < 0.0 Neb No Mean 87.82 82.94 94.06	SD 9.89 19.14 7.5 12.59 6.3 001); P 0001); P 0001); P 0001); P 0001); P 0001); P 0001); P 0001); P 0001); P	Total 35 60 25 50 30 200 - 85% line Total 40 60 30 130	19.0% 18.5% 21.5% 19.6% 21.3% 100.0% Weight 46.6% 17.3%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.63, -10.41] -7.97 [-1.41, 4.1.80]	IV, Random, 95% CI	
	Hussain et al Misra et al Sheth et al Shrth et al Suryawanshi et al Total (95% Cl) Heterogenetty: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenetty: Tau ² =	Mean 84.46 12 75.96 13. 104.16 5. 81.56 13. 83.690; Chi ² = 2 2 2 = 2.63 (P = 0 Neb Dexmede Mean 74.2 5. 74.97 12 82.63 8 1.60; Chi ² = 2.: 1.60; Chi ² = 2.:	SD Total 3.5 35 41 600 44 25 33 50 554 30 200 200 6.33, df = 4 .008} 37 tomidine 50 50 Total 37 40 .4 60 .4 30 130 70, df = 2 (P	Mean 91.22 83.6 104.12 89.56 96.63 4 (P < 0.0 Neb No Mean 87.82 82.94 94.06	SD 9.89 19.14 7.5 12.59 6.3 001); P 0001); P 0001); P 0001); P 0001); P 0001); P 0001); P 0001); P 0001); P	Total 35 60 25 50 30 200 - 85% line Total 40 60 30 130	19.0% 18.5% 21.5% 19.6% 21.3% 100.0% Weight 46.6% 17.3% 36.1%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.83, -10.41] -7.97 [-1.41, 4.1.80] -11.43 [-15.30, -7.56]	IV, Random, 95% CI	100
	Hussain et al Misra et al Sheth et al Shrkhastava et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² – Test for overall effect: Study or Subgroup Kalla et al Misra et al Total (95% Cl)	Mean 84.46 12 75.96 13. 104.16 5. 81.56 13. 83.690; Chi ² = 2 2 2 = 2.63 (P = 0 Neb Dexmede Mean 74.2 5. 74.97 12 82.63 8 1.60; Chi ² = 2.: 1.60; Chi ² = 2.:	SD Total 3.5 35 41 600 44 25 33 50 554 30 200 200 6.33, df = 4 .008} 37 tomidine 50 50 Total 37 40 .4 60 .4 30 130 70, df = 2 (P	Mean 91.22 83.6 104.12 89.56 96.63 4 (P < 0.0 Neb No Mean 87.82 82.94 94.06	SD 9.89 19.14 7.5 12.59 6.3 001); P 0001); P 0001); P 0001); P 0001); P 0001); P 0001); P 0001); P 0001); P	Total 35 60 25 50 30 200 - 85% line Total 40 60 30 130	19.0% 18.5% 21.5% 19.6% 21.3% 100.0% Weight 46.6% 17.3% 36.1%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.83, -10.41] -7.97 [-1.41, 4.1.80] -11.43 [-15.30, -7.56]	IV, Random, 95% CI	
	Hussain et al Misra et al Sheth et al Shrhwastava et al Suryawanshi et al Total (95% Cl) Heterogenethy: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenethy: Tau ² = Test for overall effect:	Mean 84.46 12 75.96 13. 104.16 5. 81.56 13. 83 63 30.90; Ch² = 2 2 z = 2.63 (P = 0 Neb Dexmede Mean 74.2 5. 74.97 12 82.63 8 1.60; Ch² = 2.: Z Z = 8.40 (P < 0	SD Total 0.5 35 41 60 42 53 33 50 54 30 200 200 6.33, df = 4 408 10068 30 137 40 130 130 70, df = 2 (P 00001) tomidine 130	Mean 91.22 83.6 104.12 89.56 96.63 4 (P < 0.0 Neb No Mean 87.82 82.94 94.06 2 = 0.26); Neb No	SD 9.89 19.14 7.55 12.59 6.3 001); t ² ormal Sa 8.84 21 6.83 t ² = 269	Total 35 60 25 50 30 200 = 85% Iline Total 40 60 30 130 6	19.0% 18.5% 21.5% 21.5% 21.3% 100.0% Weight 46.6% 17.3% 36.1% 100.0%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.83] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.83, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference	IV, Random, 95% CI	
	Hussain et al Misra et al Sherh et al Shrhvastava et al Shrhvastava et al Total (95% Cl) Heterogenetty: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Total (95% Cl) Heterogenetty: Tau ² = Test for overall effect: Study or Subgroup	Mean 84.48 1; 75.96 13. 104.16 5. 81.56 13. 83 6. $30.90;$ Ch ² = 2 2 $Z = 2.63$ ($P = 0$ Neb Dexmeder Mean 74.97 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 5. 74.97 6. 80.90 9.00 Neb Dexmeder Mean	SD Total 0.5 35 41 60 44 60 43 50 54 30 55 30 56 34, 46 50 54 100 6.33, df = 4 0008) 100 100001) 130 1000001 130 100001 100 100001 100	Mean 91.22 83.66 104.12 89.56 96.63 4 (P < 0.0 Neb No Mean 87.82 82.94 94.06 P = 0.26); Neb No Mean	SD 9.89 19.14 7.55 12.59 6.3 001); r ² 0001); r ² 8.84 21 6.83 r ² = 269 primal Sa SD	Total 35 60 25 50 30 200 - 85% Iline Total 130 4 130	19.0% 18.5% 21.5% 21.3% 100.0% Weight 100.0% Weight	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.83] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.83, -10.41] -7.97 [-1.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI	IV, Random, 95% CI	
f) Effect on HR at 6 minute	Hussain et al Misra et al Sheth et al Sheth et al Suryawanshi et al Total (95% Cl) Heterogenelty: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenelty: Tau ² = Test for overall effect: Study or Subgroup Kalia et al	Mean 84.48 12 75.96 13. 104.16 5. 81.56 13. 83 6. 30.90; Ch² = 2 2 z = 2.63 (P = 0) 0 Neb Dexmede Mean 74.2 5. 74.97 12 2 = 8.40 (P < 0)	SD Total 0.5 35 41 60 44 53 33 50 54 30 55 30 50 54 30 50 50 Total 37 40 .4 60 .4 30 130 70, df = 2 (P .00001) 100 tomidine 50 SD Total 84 40	Mean 91.22 83.6 104.12 89.56 96.63 4 (P < 0.0 Neb Nc Mean 87.82 82.94 94.06 P = 0.26); Neb Nc Mean 89 89 80 80 80 80 80 80 80 80 80 80 80 80 80	SD 9.89 9.9.9 19.14 7.55 12.59 6.3 6.83 0001); t ² 8.84 21 6.83 t ² = 269 9.89 10.86 10.86	Total 35 60 25 50 300 200 = 85% Total 40 60 30 130 4 130 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	19.0% 18.5% 21.5% 19.6% 21.3% 100.0% Weight 46.6% 17.3% 36.1% 100.0% Weight 34.8%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] -0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.83] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -16.67 [-20.35, -12.98]	IV, Random, 95% CI	
	Hussain et al Misra et al Sheth et al Shrhvastava et al Suryawanshi et al Total (95% Cl) Heterogenethy: Tau ² – Test for overall effect: Study or Subgroup Kalla et al Misra et al Total (95% Cl) Heterogenethy: Tau ² – Test for overall effect: Study or Subgroup Kalla et al Misra et al	Mean 84.48 12 75.96 13. 104.16 5. 81.56 13. 83 8. 30.90; Chi ² - 2 2 Z - 2.63 (P = 0 Neb Dexmeded Mean 74.97 12 82.63 8 1.60; Chi ² - 2. 2 Z - 8.40 (P < 0	SD Total 0.5 35 41 60 44 60 44 60 44 60 54 30 50 54 30 50 66.33, df = 4 0008 130 70 6f = 2 (P. 00001) 1000001) 130 1000001 130 1000001 130 1000001 130 100001 130 100001 130 100001 130 100001 130 100001 130 100001 130 100001 130 100001 130 100001 130 100001 130 100001 130 100001 130 100001 130 100001 130 1000001 130 10000000 130 1000000	Mean 91.22 83.6 104.12 89.56 96.63 4 (P < 0.0 Neb No Mean 87.82 82.94 94.06 P = 0.26); Neb No Mean 89 80.77	SD 9.89 19.14 7.55 12.59 6.3 0001); P 6.84 0001); P 8.84 21 6.83 Prmal Sa 5D 10.86 10.86 14.65 14.65	Total 35 600 255 50 300 2000 = 85% 10ne Total 40 60 30 130 5 5 10ne 130 5 6 10 6 0 9 6 0 130 5 6 10 10 10 10 10 10 10 10 10 10 10 10 10	19.0% 18.5% 21.5% 21.5% 21.3% 19.6% 21.3% 19.6% 21.3% 19.6% 21.3% 100.0% Weight 36.1% 100.0%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.06, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.83, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -16.67 [-20.35, -12.98] -7.22 [-1.15, -2.2.98]	IV, Random, 95% CI	
f) Effect on HR at 6 minute	Hussain et al Misra et al Sheth et al Shrhwastava et al Suryawanshi et al Total (95% Cl) Heterogenethy: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenethy: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Suryawanshi et al	Mean 84.48 12 75.96 13. 104.16 5. 81.56 13. 83 8. 30.90; Chi ² - 2 2 Z - 2.63 (P = 0 Neb Dexmeded Mean 74.97 12 82.63 8 1.60; Chi ² - 2. 2 Z - 8.40 (P < 0	SD Total 0.5 35 41 60 42 53 33 50 54 30 554 30 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 704 84 40 87 60 67 60	Mean 91.22 83.6 104.12 89.66 99.63 4 (P < 0.0 Neb No Mean 87.82 82.94 94.06 P = 0.26); Neb No Mean 89 80.77 90.2	SD 9.89 9.9.9 19.14 7.55 12.59 6.3 6.83 0001); t ² 8.84 21 6.83 t ² = 269 9.89 10.86 10.86	Total 35 600 255 500 300 2000 = 85% Iline Total 40 60 30	19.0% 18.5% 21.5% 21.5% 21.3% 19.6% 21.3% 19.6% 21.3% 100.0% Weight 36.1% 100.0% Weight 34.8% 31.6% 33.6%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.68, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.63, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -16.67 [-20.35, -12.99] -7.22 [-12.15, -2.29] -7.26 [-12.15, -2.29] -8.60 [-12.77, -4.43]	IV, Random, 95% CI	
f) Effect on HR at 6 minute	Hussain et al Misra et al Sheth et al Shrat et al Shrat et al Shrat et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Surgawanshi et al Total (95% Cl)	Mean 84.48 1; 75.96 13. 104.16 5. 81.56 13. 83 8. 30.90; Ch ² = 2 2.63 ($P = 0$ Neb Dexmede Mean 74.2 5. 74.2 5. 82.63 6 1.60; Ch ² = 2.: 2 2 8.40 ($P < 0$ Neb Dexmede Mean 72.33 4. 73.55 12. 81.6 6.	SD Total 0.5 35 41 60 42 33 50 54 30 50 54 30 50 54 30 50 50 Total 37 40 37 40 34 30 130 70, df = 2 (P. 000001) 130 tomidine 50 50 Total 84 40 87 60 74 30	Mean 91.22 83.66 96.63 96.63 4 (P < 0.0 Neb No Mean 87.82 82.94 94.06 P = 0.26); Neb No Mean 89.90.2	SD 9.89 9.89 9.89 9.89 9.89 19.14 7.5 12.59 6.3 12.59 6.3 001); i' i' mmal Sa SD 8.84 21 11.6 8.84 21 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.34 2.61 12.61 12.51	Total 355 600 255 500 300 2000 = 85% Total 130 40 40 30 130	19.0% 18.5% 21.5% 21.5% 21.3% 19.6% 21.3% 19.6% 21.3% 19.6% 21.3% 100.0% Weight 36.1% 100.0%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.06, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.83, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -16.67 [-20.35, -12.98] -7.22 [-1.15, -2.2.98]	IV, Random, 95% CI	
f) Effect on HR at 6 minute	Hussain et al Misra et al Sheth et al Sheth et al Sheth et al Suryawanshi et al Total (95% Cl) Heterogenelty: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Total (95% Cl) Heterogenelty: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenelty: Tau ² =	Mean 84.48 12 75.96 13. 104.16 5. 81.56 13. 83 6. 30.90; Ch² = 2 2 z = 2.63 (P = 0 Neb Dexmede Mean 74.2 5. 74.97 12 82.63 6 1.60; Ch² = 2. 2 Z = 8.40 (P < 0	SD Total 0.5 35 41 60 42 53 33 50 54 30 55 30 50 54 30 50 50 Total 37 40 2.4 60 5.4 30 130 7 70, df = 2 (P 00001) tomidine 50 50 Total 84 40 84 40 130 74 84 40 130 74 84 40 130 130 74 30 130 130	Mean 91.22 83.66 96.63 96.63 4 (P < 0.0 Neb No Mean 87.82 82.94 94.06 P = 0.26); Neb No Mean 89.90.2	SD 9.89 9.89 9.89 9.89 9.89 19.14 7.5 12.59 6.3 12.59 6.3 001); i' i' mmal Sa SD 8.84 21 11.6 8.84 21 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.34 2.61 12.61 12.51	Total 355 600 255 500 300 2000 = 85% Total 130 40 40 30 130	19.0% 18.5% 21.5% 21.5% 21.3% 19.6% 21.3% 19.6% 21.3% 100.0% Weight 36.1% 100.0% Weight 34.8% 31.6% 33.6%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.68, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.63, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -16.67 [-20.35, -12.99] -7.22 [-12.15, -2.29] -7.26 [-12.15, -2.29] -8.60 [-12.77, -4.43]	IV, Random, 95% CI	
f) Effect on HR at 6 minute	Hussain et al Misra et al Sheth et al Shrat et al Shrat et al Shrat et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Surgawanshi et al Total (95% Cl)	Mean 84.48 12 75.96 13. 104.16 5. 81.56 13. 83 6. 30.90; Ch² = 2 2 z = 2.63 (P = 0 Neb Dexmede Mean 74.2 5. 74.97 12 82.63 6 1.60; Ch² = 2. 2 Z = 8.40 (P < 0	SD Total 0.5 35 41 60 42 53 33 50 54 30 55 30 50 54 30 50 50 Total 37 40 2.4 60 5.4 30 130 7 70, df = 2 (P 00001) tomidine 50 50 Total 84 40 84 40 130 74 84 40 130 74 84 40 130 130 74 30 130 130	Mean 91.22 83.66 96.63 96.63 4 (P < 0.0 Neb No Mean 87.82 82.94 94.06 P = 0.26); Neb No Mean 89.90.2	SD 9.89 9.89 9.89 9.89 9.89 19.14 7.5 12.59 6.3 12.59 6.3 001); i' i' mmal Sa SD 8.84 21 11.6 8.84 21 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.34 2.61 12.61 12.51	Total 355 600 255 500 300 2000 = 85% Total 130 40 40 30 130	19.0% 18.5% 21.5% 21.5% 21.3% 19.6% 21.3% 19.6% 21.3% 100.0% Weight 36.1% 100.0% Weight 34.8% 31.6% 33.6%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.68, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.63, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -16.67 [-20.35, -12.99] -7.22 [-12.15, -2.29] -7.26 [-12.15, -2.29] -8.60 [-12.77, -4.43]	IV, Random, 95% CI	100
f) Effect on HR at 6 minute	Hussain et al Misra et al Sheth et al Sheth et al Sheth et al Suryawanshi et al Total (95% Cl) Heterogenelty: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Total (95% Cl) Heterogenelty: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenelty: Tau ² =	Mean 84.48 12 75.96 13. 104.16 5. 81.56 13. 83 6. 30.90; Ch² = 2 2 z = 2.63 (P = 0 Neb Dexmede Mean 74.2 5. 74.97 12 82.63 6 1.60; Ch² = 2. 2 Z = 8.40 (P < 0	SD Total 0.5 35 41 60 44 62 33 50 54 30 55 700 6.33, df = 4 0008) 130 70, df = 2 (P 00001) 130 130 70, df = 2 (P 00001) 130 200011 130 200011	Mean 91.22 83.66 96.63 96.63 96.63 87.82 82.94 94.06 94.06 94.06 94.06 82.94 94.06 2 = 0.26); 88.94 94.06 2 = 0.26); 80.77 90.2	SD 9.89 9.89 9.89 9.89 9.89 19.14 7.5 12.59 6.3 12.59 6.3 001); i' i' mmal Sa SD 8.84 21 11.6 8.84 21 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.33 12.59 6.34 2.61 12.61 12.51	Total 355 600 255 500 2000 2000 2000 2000 2000	19.0% 18.5% 21.5% 21.5% 21.3% 19.6% 21.3% 19.6% 21.3% 100.0% Weight 36.1% 100.0% Weight 34.8% 31.6% 33.6%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.68, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.63, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -12.62, 5, -12.99] -7.22 [-12.15, -2.29] -7.22 [-12.15, -2.29] -8.60 [-12.77, -4.43] -10.97 [-17.04, -4.91] Mean Difference	IV, Random, 95% CI	100
f) Effect on HR at 6 minute	Hussain et al Misra et al Sheth et al Shrat et al Shrat et al Shrat et al Total (95% Cl) Heterogeneity: Tau ² – Test for overall effect: Study or Subgroup Kalla et al Misra et al Surgawanshi et al Total (95% Cl) Heterogeneity: Tau ² – Test for overall effect: Study or Subgroup Kalla et al Misra et al Surgawanshi et al Total (95% Cl) Heterogeneity: Tau ² – Test for overall effect: Study or Subgroup	Mean 84.48 12 75.96 13. 104.16 5. 81.56 13. 83 6. 30.90; Ch ² = 2 2 Z = 2.63 ($P = 0$ Neb Dexmeded Mean 2 74.97 12 82.63 8 1.60; Ch ² = 2.: 2 Z = 8.40 ($P < 0$ Neb Dexmeded Mean 72.33 4. 73.55 12. 81.6 8. 23.95; Ch ² = 1 Z Neb Dexmeded Mean Neb Dexmeded Mean	SD Total 0.5 35 41 60 44 60 44 60 44 20 33 50 54 30 554 30 500 54 30 50 50 Total 37 40 2.4 60 8.4 30 130 00001) tomidine 50 50 Total 84 40 87 60 74 30 130 7004 2.28, df = 2 30 0004) 130 2.28, df = 2 00004	Mean 91.22 83.66 96.63 4 (P < 0.0 Neb No Mean 87.82 82.94 94.06 P = 0.26); Neb No Mean 89.92 (P = 0.0 Neb No Mean	SD 9.89 9.89 9.89 9.89 6.3 12.59 6.3 001); i² 6.84 21 6.83 i² 263 10.86 14.65 10.86 7.71 002); i² = 50	Total 355 600 255 500 2000 = 85% line Total 400 600 30 130 84% line Total 130	19.0% 18.5% 21.5% 19.6% 21.3% 100.0% Weight 46.6% 17.3% 36.1% 100.0% Weight 100.0% Weight 100.0%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.83, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -7.22 [-1.51, -2.29] -8.60 [-12.77, -4.43] -10.97 [-17.04, -4.91] Mean Difference IV, Random, 95% CI	IV, Random, 95% CI	100
f) Effect on HR at 6 minute g) Effect on HR at 8 minute	Hussain et al Misra et al Sheth et al Sheth et al Sheth et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalia et al	Mean 84.48 12 75.96 13. 104.16 5. 81.56 13. 83 8. 30.90; Ch² = 2 2 $Z = 2.63$ ($P = 0$ Neb Dexmede Mean 74.2 74.2 5. 74.97 12 2.60; Ch² = 2.: 2 Z = 8.40 ($P < 0$ Neb Dexmede Mean 72.33 4. 73.55 12. 81.6 8. 23.95; Chl² = 1 2 Neb Dexmede Mean 73.6 4.	SD Total 0.5 35 41 60 44 25 33 50 54 30 55 30 50 54 30 50 55 Total 37 40 2.4 60 1.4 30 130 70, df = 2 (P 0.0001) 130 tomidine 5D 5D Total 84 40 87 60 130 130 2.28, df = 2 0.004) 130 130 2.28, df = 2 0.004) 130 130 2.28, df = 2 0.004)	Mean 91.22 83.66 96.63 96.63 96.63 87.82 82.94 94.06 2 = 0.26); Neb Nc Mean 89 80.77 90.2 2 (P = 0.00 Neb Nc Mean 89.54	SD 9.89 9.89 9.80 9.63 12.59 6.3 0001); ^p 5D 8.84 21 6.83 ^p - 269 10.86 14.65 7.71 10.86 14.65 5D 10.86 14.65 5D 11.96	Total 355 600 255 500 2000 = 85% Total 130 60 30 130 64% 130 84%	19.0% 18.5% 21.5% 21.5% 19.6% 21.3% 19.6% 19.6% 19.6% 19.6% 19.6% 19.6% 100.0% Weight 34.6% 31.6% 33.6% 100.0% Weight 20.4%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.68, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -11.45 [-16.83, -10.41] -7.97 [-14.14, -1.80] -11.45 [-16.83, -10.41] -7.97 [-14.14, -1.80] -11.45 [-14.52, -9.09] Mean Difference IV, Random, 95% CI -16.67 [-20.35, -12.99] -7.22 [-12.15, -2.29] -8.60 [-12.77, -4.43] -10.97 [-17.04, -4.91] Mean Difference IV, Random, 95% CI -15.98 [-10.99, -12.02]	IV, Random, 95% CI	100
f) Effect on HR at 6 minute	Hussain et al Misra et al Sheth et al Shrhwastava et al Shrhwastava et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Study or Subgroup Kalla et al Misra et al	Mean 84.48 1; 75.96 13, 104.16 5, 81.56 13, 83 8, 30.90; Chi ² = 2 2 Z = 2.63 (P = 0 Neb Dexmeded Mean 74.97 12 82.63 8 1.60; Chi ² = 2. 2 Z = 8.40 (P < 0	SD Total 0.5 35 41 60 44 60 44 60 44 60 54 30 50 54 30 50 54 30 554 30 50 54 30 50 50 Total 37 40 4.4 60 8.4 30 130 70, df = 2 (P. 000001) Total 84 40 87 60 74 30 130 70 and fe = 2 00001) Total 84 40 87 60 74 30 130 2.28, df = 2 00004) Total 50 Total 88 40 85 60	Mean 91.22 83.66 96.63 96.63 96.63 96.63 96.63 87.82 82.94 94.06 94.06 94.06 92.94 94.06 92.94 94.06 92.92 82.94 94.06 92.22 82.94 94.06 92.22 82.94 94.06 92.22 82.94 94.06 92.22 82.94 94.06 92.22 82.95 80.77 90.2 22 (P = 0.00 89.58 78.06 85.58 78.06	SD 9.89 19.14 7.55 12.59 6.3 0001); ^p mmal Sa SD 8.84 21 6.83 rf 2 260 10.86 7.71 10.86 7.71 10.85 7.71 10.85 7.71 10.45 5.771	Total 355 600 255 500 2000 = 85% Iline Total 40 60 300 84% Iline Total 40 60 300 84%	19.0% 18.5% 21.5% 21.3% 21.3% 19.6% 21.3% 19.6% 21.3% 19.6% 21.3% 100.0% Weight 34.6% 31.6% 33.6% 100.0% Weight 20.4% 19.9%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.68, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.63, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -7.22 [-2.15, -2.28] -8.60 [-12.77, -4.43] -10.97 [-17.04, -4.91] Mean Difference IV, Random, 95% CI -15.98 [-19.94, -12.02] -6.80 [-11.27, -2.38]	IV, Random, 95% CI	100
f) Effect on HR at 6 minute g) Effect on HR at 8 minute	Hussain et al Misra et al Sheth et al Sheth et al Sheth et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalia et al	Mean 84.48 12 75.96 13. 104.16 5. 81.56 13. 83 8. 30.90; Ch² = 2 2 $Z = 2.63$ ($P = 0$ Neb Dexmede Mean 74.2 74.2 5. 74.97 12 2.60; Ch² = 2.: 2 Z = 8.40 ($P < 0$ Neb Dexmede Mean 72.33 4. 73.55 12. 81.6 8. 23.95; Chl² = 1 2 Neb Dexmede Mean 73.6 4.	SD Total 0.5 35 41 60 42 33 50 54 30 50 54 30 55 703 50 Total 50 Total 50 Total 50 Total 60 34 37 40 2.4 60 3.4 30 130 130 70, df = 2 (P. 0.00001) 130 100 74 130 130 2.28, df = 2 .0004) 130 138 40 85 40 85 60 45 25	Mean 91.22 83.66 96.63 96.63 8 (P < 0.0 Neb No Mean 87.82 82.94 94.06 94	SD 9.89 19.14 7.55 12.59 6.3 0001); ^p mmal Sa SD 8.84 21 6.83 rf 2 260 10.86 7.71 10.86 7.71 10.85 7.71 10.85 7.71 10.45 5.771	Total 355 600 255 500 2000 = 85% Total 130 60 30 130 64% 130 84%	19.0% 18.5% 21.5% 21.5% 19.6% 21.3% 19.6% 21.3% 19.6% 100.0% Weight 36.1% 36.1% 31.6% 31.6% 31.6% 31.6% 31.6% 32.6% 100.0%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.68, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -11.45 [-16.83, -10.41] -7.97 [-14.14, -1.80] -11.45 [-16.83, -10.41] -7.97 [-14.14, -1.80] -11.45 [-14.52, -9.09] Mean Difference IV, Random, 95% CI -16.67 [-20.35, -12.99] -7.22 [-12.15, -2.29] -8.60 [-12.77, -4.43] -10.97 [-17.04, -4.91] Mean Difference IV, Random, 95% CI -15.98 [-10.99, -12.02]	IV, Random, 95% CI	100
f) Effect on HR at 6 minute g) Effect on HR at 8 minute	Hussain et al Misra et al Sheth et al Sheth et al Shrat et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Kalla et al Misra et al Sheth et al	$\begin{array}{c} \mbox{Mean} \\ \mbox{84.48} & 12 \\ \mbox{75.96} & 13 \\ \mbox{75.96} & 13 \\ \mbox{104.16} & 5 \\ \mbox{81.66} & 13 \\ \mbox{83.68} \\ \mbox$	SD Total 0.5 35 41 60 42 33 50 54 30 50 54 30 50 54 30.008) 37 50 Total 37 40 54 30 6.33, df = 4 30 6.34, 430 130 70.0001) Total 84 40 87 60 130 70a 2.28, df = 2 .0004) Total 48 40 48 40 48 40 48 40 48 40 48 40 48 40 48 40 48 40 40 40 40 40 40 40 40 40 50 40 <t< td=""><td>Mean 91.22 83.66 96.63 96.63 96.63 96.63 96.63 96.63 87.82 82.94 94.06 94.06 94.06 94.06 94.06 92.02 82.94 94.06 94.06 92.22 (P = 0.0) Neb No Mean 89 80.77 90.2 2 (P = 0.0) Neb No Mean 89 80.72 90.2 2 (P = 0.0) Neb No Mean 89 80.72 90.2 2 (P = 0.0) 80.7 80.7 80.7 80.7 80.7 80.7 80.7 80.7</td><td>SD 9.89 9.89 19.14 7.5 12.59 6.3 0001); ^p rrmal Sa SD 0001); ^p rrmal Sa SD 10.86 14.65 7.71 10.86 14.65 11.96 13.95 6.33</td><td>Total 355 600 255 500 2000 = 85% Total 400 600 300 1300 84% lline Total 400 84% lline Total 400 250 1300 2000 2000 2000 2000 2000 2000 200</td><td>19.0% 18.5% 21.5% 21.5% 19.6% 21.3% 19.6% 21.3% 19.6% 19.6% 21.3% 100.0% Weight 36.1% 100.0% Weight 34.8% 31.6% 33.6% Weight 20.4% 19.9% 21.5%</td><td>IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.68, -2.92] -13.63 [-17.43, -9.83] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.83, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -16.67 [-20.35, -12.99] -7.22 [-12.15, -2.29] -8.60 [-12.77, -4.43] -10.97 [-17.04, -4.91] Mean Difference IV, Random, 95% CI -15.98 [-19.94, -12.02] -6.80 [-1.27, -2.33] -0.44 [-3.79, 2.91]</td><td>IV, Random, 95% CI</td><td>100</td></t<>	Mean 91.22 83.66 96.63 96.63 96.63 96.63 96.63 96.63 87.82 82.94 94.06 94.06 94.06 94.06 94.06 92.02 82.94 94.06 94.06 92.22 (P = 0.0) Neb No Mean 89 80.77 90.2 2 (P = 0.0) Neb No Mean 89 80.72 90.2 2 (P = 0.0) Neb No Mean 89 80.72 90.2 2 (P = 0.0) 80.7 80.7 80.7 80.7 80.7 80.7 80.7 80.7	SD 9.89 9.89 19.14 7.5 12.59 6.3 0001); ^p rrmal Sa SD 0001); ^p rrmal Sa SD 10.86 14.65 7.71 10.86 14.65 11.96 13.95 6.33	Total 355 600 255 500 2000 = 85% Total 400 600 300 1300 84% lline Total 400 84% lline Total 400 250 1300 2000 2000 2000 2000 2000 2000 200	19.0% 18.5% 21.5% 21.5% 19.6% 21.3% 19.6% 21.3% 19.6% 19.6% 21.3% 100.0% Weight 36.1% 100.0% Weight 34.8% 31.6% 33.6% Weight 20.4% 19.9% 21.5%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.68, -2.92] -13.63 [-17.43, -9.83] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.83, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -16.67 [-20.35, -12.99] -7.22 [-12.15, -2.29] -8.60 [-12.77, -4.43] -10.97 [-17.04, -4.91] Mean Difference IV, Random, 95% CI -15.98 [-19.94, -12.02] -6.80 [-1.27, -2.33] -0.44 [-3.79, 2.91]	IV, Random, 95% CI	100
f) Effect on HR at 6 minute g) Effect on HR at 8 minute	Hussain et al Misra et al Sheth et al Sheth et al Sheth et al Shyawanshi et al Total (95% Cl) Heterogenelty: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenelty: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenelty: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Shrkatava et al Shrkatava et al Suryawanshi et al	Mean 84.48 1; 75.96 13, 104.16 5, 81.56 13, 83 8, 30.90; Chi ² = 2 2 Z = 2.63 (P = 0 Neb Dexmeded Mean 74.97 12 82.63 8 1.60; Chi ² = 2. Z Z = 8.40 (P < 0	SD Total 0.5 35 41 60 42 63 33 50 50 54 30 50 54 30 554 30 500 54 500 54 500 54 500 54 500 54 500 130 50 Total 84 40 84 40 84 40 87 60 130 2.28, df = 2 0.0004) 130 130 2.28, df = 2 0.0004 130 130 2.28, df = 2 0.0004 130 0.2.28, df = 2 25 0.004 50 0.005 20 0.005 30	Mean 91.22 83.66 96.63 96.63 96.63 96.63 96.63 96.63 87.82 82.94 94.06 94.06 94.06 94.06 94.06 92.02 82.94 94.06 94.06 92.22 (P = 0.0) Neb No Mean 89 80.77 90.2 2 (P = 0.0) Neb No Mean 89 80.72 90.2 2 (P = 0.0) Neb No Mean 89 80.72 90.2 2 (P = 0.0) 80.7 80.7 80.7 80.7 80.7 80.7 80.7 80.7	SD 9.89 9.89 19.14 7.5 12.59 6.3 0001); ^p rrmal Sa SD 0001); ^p rrmal Sa SD 10.86 14.65 7.71 10.86 14.65 11.96 13.95 6.33	Total 355 600 255 500 300 2000 = 85% 1000 600 300 130 600 300 130 64% 1000 84%	19.0% 18.5% 21.5% 21.5% 21.3% 19.6% 21.3% 19.6% 21.3% 46.6% 17.3% 36.1% 100.0% Weight 34.6% 31.6% 33.6% 100.0% Weight 20.4% 19.9% 21.5% 20.5%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.63, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -12.62, 5, -12.99] -7.22 [-12.15, -2.28] -8.60 [-12.77, -4.43] -10.97 [-17.04, -4.91] Mean Difference IV, Random, 95% CI -15.98 [-19.94, -12.02] -6.80 [-11.27, -2.33] -0.44 [-3.79, 2.91] -7.26 [-1.28, -1.65] -7.00 [-11.29, -2.71]	IV, Random, 95% CI	100
f) Effect on HR at 6 minute g) Effect on HR at 8 minute	Hussain et al Misra et al Sheth et al Sheth et al Shravastava et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² – Test for overall effect: Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² – Test for overall effect: Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² – Test for overall effect: Study or Subgroup Kalla et al Misra et al Sheth et al Sheth et al Sheth et al Shravastava et al Suryawanshi et al Total (95% Cl)	Mean 84.48 1; 75.96 13. 104.16 5. 81.56 13. 83 6. 30.90; Ch² = 2 2 Z = 2.63 (P = 0 Neb Dexmeded Mean 2 74.9 1. 82.63 8 1.60; Ch² = 2: 2. 2 = 8.40 (P < 0	SD Total 0.5 35 41 60 44 60 44 60 44 60 54 30 50 54 30 50 54 30 55 36 50 70 50 70 50 70 70 dF = 2 (P. 000001) 130 130 000001) tomidine 50 70 dF = 2 (P. 000001) 130 2.28, df = 2 0.0004) 130 70, df = 30 00041 130 130 2.28, df = 2 00043 500 85 60 85 60 85 60 862 30	Mean 91.22 83.66 96.63 4 (P < 0.0 Neb No Mean 87.82 82.94 94.06 P = 0.26); Neb No Mean 89 80.77 90.2 2 (P = 0.0 Neb No Mean 89 80.77 90.2 2 (P = 0.0	SD 9.89 19.14 7.55 12.59 6.3 0001); ² mmal Sa 5D 10.86 8.84 1 - 269 10.86 7.71 10.96 7.71 10.95 6.59 14.44 8.11	Total 355 600 255 500 300 2000 = 85% Hilne Total 130 600 300 1300 84% Hilne Total 130 600 300 1300 84% Hilne 700 1300 84% Hille 700 1300 84% Hille 700 255 00 2000 2000 2000 2000 2000 200	19.0% 18.5% 21.5% 21.5% 21.3% 19.6% 21.3% 19.6% 21.3% 19.6% 21.3% 19.6% 21.3% 21.5% 19.6% 21.5% 21	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.68, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.63, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -16.67 [-20.35, -12.99] -7.22 [-12.15, -2.29] -8.60 [-12.77, -4.43] -10.97 [-17.04, -4.91] Mean Difference IV, Random, 95% CI -15.98 [-19.94, -12.02] -6.80 [-11.27, -2.31] -0.44 [-3.79, 2.91] -7.24 [-12.83, -1.65]	IV, Random, 95% CI IV, Ra	100
f) Effect on HR at 6 minute g) Effect on HR at 8 minute	Hussain et al Misra et al Sheth et al Sheth et al Sheth et al Shyawanshi et al Total (95% Cl) Heterogenelty: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenelty: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenelty: Tau ² = Test for overall effect: Study or Subgroup Kalia et al Misra et al Shrkatava et al Shrkatava et al Suryawanshi et al	$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	SD Total 0.5 35 41 60 44 60 643 30 50 54 30 50 54 30 55 Total 36 50 50 Total 37 40 50 Total 37 40 130 70 70 40 130 70 50 Total 84 40 87 60 74 30 130 2.28, df = 2 .0004) 130 130 130 130 130 148 40 85 60 45 25 862 30 205 205	Mean 91.22 83.66 96.63 4 (P < 0.0 Neb No Mean 87.82 82.94 94.06 P = 0.26); Neb No Mean 89 80.77 90.2 2 (P = 0.0 Neb No Mean 89 80.77 90.2 2 (P = 0.0	SD 9.89 19.14 7.55 12.59 6.3 0001); ² mmal Sa 5D 10.86 8.84 1 - 269 10.86 7.71 10.96 7.71 10.95 6.59 14.44 8.11	Total 355 600 255 500 300 2000 = 85% Hilne Total 130 600 300 1300 84% Hilne Total 130 600 300 1300 84% Hilne 700 1300 84% Hille 700 1300 84% Hille 700 255 00 2000 2000 2000 2000 2000 200	19.0% 18.5% 21.5% 21.5% 21.3% 19.6% 21.3% 19.6% 21.3% 46.6% 17.3% 36.1% 100.0% Weight 34.6% 31.6% 33.6% 100.0% Weight 20.4% 19.9% 21.5% 20.5%	IV, Random, 95% CI -6.74 [-12.28, -1.20] -7.64 [-13.55, -1.73] 0.04 [-3.59, 3.67] -8.00 [-13.08, -2.92] -13.63 [-17.43, -9.63] -7.16 [-12.49, -1.83] Mean Difference IV, Random, 95% CI -13.62 [-16.63, -10.41] -7.97 [-14.14, -1.80] -11.43 [-15.30, -7.56] -11.85 [-14.62, -9.09] Mean Difference IV, Random, 95% CI -12.62, 5, -12.99] -7.22 [-12.15, -2.28] -8.60 [-12.77, -4.43] -10.97 [-17.04, -4.91] Mean Difference IV, Random, 95% CI -15.98 [-19.94, -12.02] -6.80 [-11.27, -2.33] -0.44 [-3.79, 2.91] -7.26 [-1.28, -1.65] -7.00 [-11.29, -2.71]	IV, Random, 95% CI	100

Fig. 2 Effect of nebulized dexmedetomidine on heart rate

Risk of bias assessment

According to RoB2 tool, three out of six included studies had a high risk of bias (Fig. 6). All the included studies described the method of randomization and were considered low risk except Sheth et al. and Kaila et al. which although mentioned that patients were randomized into two groups but the method of randomization was not mentioned [17, 20]. Suryawanshi et al.

			medetom			ormal Sal			Mean Difference	Mean Difference	
	Study or Subgroup	Mean	SD	Total	Mean	SD	-	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
a) Effect on SBP at 1 minute	Hussain et al Misra et al	124.6 148.32	13.87		133.74 129.85	11.24	35	23.4%	-9.14 [-15.05, -3.23] 18.47 [-13.93, 50.87]		
a) Ellect on SBP at 1 minute	Sheth et al	114.88	12.65		124.96	7.41	25	23.6%	-10.08 [-15.83, -4.33]	-	
	Shrivastava et al	113.2	14.5		125.92		50	23.5%	-12.72 [-18.55, -6.89]	+	
	Suryawanshi et al	113.46	8.38	30	136.36	8.04	30	25.3%	-22.90 [-27.06, -18.74]	*	
	Total (95% CI)			200			200	100.0%	-12.48 [-19.85, -5.10]	•	
	Heterogeneity: Tau ² =				(P < 0.0	001); P -	84%			-100 -50 0 50	100
	Test for overall effect:	Z = 3.32	(P = 0.000)	9)						Favours [experimental] Favours [control]	
										11 0///	=
	Study or Subgroup	Mean	medetomi SD	Total	Mean	ormal Sal SD	Total	Weight	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% CI	
b) Effect on SBP at 2 minute	Hussain et al	126.8	13.91	35	137.08	10.68	35	30.1%	-10.28 [-16.09, -4.47]		
•	Kaila et al	98.28	12.28		122.58	10.43	40		-24.30 [-29.29, -19.31]		
	Misra et al Suryawanshi et al	118.41 112.3	24.57 8.66		138.29 140.46	124.15	60 30	6.9X 31.9X			
	Sur yamansin et an	112.9	0.00	50	140.40	1.15					
	Total (95% CI)			165				100.0%	-21.00 [-30.41, -11.60]		
	Heterogeneity: Tau ² = Test for overall effect:				(P < 0.00	(01); F =	66%			-100 -50 0 50	100
	rest for overall effect.	2 = 4.30 (r < 0.000	1,						Favours [experimental] Favours [control]	
		Neb Dex	medetomi	idine	Neb No	ormal Sal	ine		Mean Difference	Mean Difference	
	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
c) Effect on SBP at 3 minute	Hussain et al Misra et al	124.6 124.39	13.87 50.45	35 60	137.4 115.07	9.81	35 60	37.4%	-12.80 [-18.43, -7.17] 9.32 [-11.06, 29.70]	*	
	Suryawanshi et al	111.4	9.24		140.86	4.86	30	38.4%	-29.46 [-33.20, -25.72]		
	Total (95% CI)	1 - 2 - 4 - 4		125				100.0%	-13.86 [-30.01, 2.29]		
	Heterogeneity: Tau ² = Test for overall effect:			2, ar =	2 (P < 0.1	,0001); 1	= 947			-100 -50 0 50	100
	rest for overall energy.		(. – 0.05)							Favours [experimental] Favours [control]	
		Neb Dex	medetomi	idine	Neb No	ormal Sal			Mean Difference	Mean Difference	
	Study or Subgroup	Mean	SD	Total	Mean	SD		Weight	IV, Random, 95% CI	IV, Random, 95% CI	
d) Effect on SBP at 4 minute	Hussain et al Kaila et al	124.6 99.18	13.87 13.66		132.25 118.58	9.7	35 40	24.8%	-7.65 [-13.26, -2.04] -19.40 [-24.89, -13.91]		
ay Encer on 501 at 4 minute	Misra et al	105.92	17.75		108.91		60	24.6%	-2.99 [-8.88, 2.90]		
	Suryawanshi et al	110.86	8.83	30	135.83	5.49	30	25.8%	-24.97 [-28.69, -21.25]	•	
	Total (95% CI)			165			165	100.0%	-13.89 [-24.33, -3.45]	•	
	Heterogeneity: Tau2 =	106.32; 0	Chl ² = 50.7		3 (P < 0.0	00001); 1			,,,	-100 -50 0 50	100
	Test for overall effect:	Z = 2.61	(P = 0.009)	1}						Favours [experimental] Favours [control]	100
	L										
		Neb De	ymedetom	nidine	Neb N	ormal Sa	line		Mean Difference	Mean Difference	
	Study or Subgroup	Neb De Mean	xmedetom SD	nidine Total	Neb N Mean	ormal Sa SD		Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% CI	
	Hussain et al	Mean 122.57	SD 13.87	Total 35	Mean 130.22	SD 9.44	Total 35	19.7%	IV, Random, 95% CI -7.65 [-13.21, -2.09]		_
e) Effect on SBP at 5 minute	Hussain et al Misra et al	Mean 122.57 103.81	SD 13.87 19.14	Total 35 60	Mean 130.22 106.09	SD 9.44 19.14	Total 35 60	19.7% 18.0%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57]		
e) Effect on SBP at 5 minute	Hussain et al	Mean 122.57	SD 13.87 19.14 12.67	Total 35 60	Mean 130.22 106.09 119.28	SD 9.44	Total 35	19.7%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12]		_
e) Effect on SBP at 5 minute	Hussain et al Misra et al Sheth et al	Mean 122.57 103.81 111.2	SD 13.87 19.14 12.67 8.34	Total 35 60 25	Mean 130.22 106.09 119.28 118.2	SD 9.44 19.14 8.4 13.55	Total 35 60 25	19.7% 18.0% 19.1% 21.1%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57]		
e) Effect on SBP at 5 minute	Hussain et al Misra et al Sheth et al Shrivastava et al Suryawanshi et al	Mean 122.57 103.81 111.2 109.86	SD 13.87 19.14 12.67 8.34	Total 35 60 25 50 30	Mean 130.22 106.09 119.28 118.2	SD 9.44 19.14 8.4 13.55	Total 35 60 25 50 30	19.7% 18.0% 19.1% 21.1% 22.1%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.26 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68]		
e) Effect on SBP at 5 minute	Hussain et al Misra et al Sheth et al Shrivastava et al	Mean 122.57 103.81 111.2 109.86 110.9	SD 13.87 19.14 12.67 8.34 8.88	Total 35 60 25 50 30 200	Mean 130.22 106.09 119.28 118.2 129.1	SD 9.44 19.14 8.4 13.55 4.26	Total 35 60 25 50 30 200	19.7% 18.0% 19.1% 21.1%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93]	IV, Random, 95% Cl	100
e) Effect on SBP at 5 minute	Hussain et al Misra et al Sheth et al Shrivastava et al Suryawanshi et al Total (95% CI)	Mean 122.57 103.81 111.2 109.86 110.9	SD 13.87 19.14 12.67 8.34 8.88 Chl ² = 25.94	Total 35 60 25 50 30 200 0, df = 4	Mean 130.22 106.09 119.28 118.2 129.1	SD 9.44 19.14 8.4 13.55 4.26	Total 35 60 25 50 30 200	19.7% 18.0% 19.1% 21.1% 22.1%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.26 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68]		100
e) Effect on SBP at 5 minute	Hussain et al Misra et al Sheth et al Shrivastava et al Suryawanshi et al Total (95% Cl) Heterogenelty: Tau ² •	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16	SD 13.87 19.14 12.67 8.34 8.88 Chl ² = 25.99 (P = 0.002	Total 35 60 25 50 30 200 0, df = 4 2)	Mean 130.22 106.09 119.28 118.2 129.1 (P < 0.0	SD 9.44 19.14 8.4 13.55 4.26 001); P	Total 35 60 25 50 30 200 85%	19.7% 18.0% 19.1% 21.1% 22.1%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51]	IV, Random, 95% CI	100
e) Effect on SBP at 5 minute	Hussain et al Misra et al Sheth et al Shrivastava et al Suryawanshi et al Total (95% Cl) Heterogenelty: Tau ² •	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16	SD 13.87 19.14 12.67 8.34 8.88 Chl ² = 25.94	Total 35 60 25 50 30 200 0, df = 4 2)	Mean 130.22 106.09 119.28 118.2 129.1 (P < 0.0	SD 9.44 19.14 8.4 13.55 4.26	Total 35 60 25 50 30 200 85%	19.7% 18.0% 19.1% 21.1% 22.1%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.26 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68]	IV, Random, 95% CI → → → → → → → → → → → → →	100'
	Hussain et al Misra et al Sheth et al Shrihvastava et al Suryawanshi et al Total (95% (1) Heterogeneity: Tau ² - Test for overall effect Study or Subgroup Kalia et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16 Neb De Mean 98.9	SD 13.87 19.14 12.67 8.34 8.88 Sh ² = 25.94 (P = 0.002 exmedetom SD 15.94	Total 35 60 25 50 30 200 0, df = 4 2} nidine Total 40	Mean 130.22 106.09 119.28 118.2 129.1 (P < 0.0 Neb N Mean 119.4	SD 9.44 19.14 8.4 13.55 4.26 0011; I ² -	Total 35 60 25 50 30 200 85%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9%	IV, Random, 95% Cl -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% Cl -20.50 [-26.83, -14.17]	IV, Random, 95% CI	100
e) Effect on SBP at 5 minute f) Effect on SBP at 6 minute	Hussain et al Misra et al Sheth et al Shr/Nastava et al Suryawanshi et al Total (95% CI) Heterogeneity: Tau ² - Test for overall effect <u>Study or Subgroup</u> Kalla et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C ; Z = 3.16 Neb De Mean 96.9 102.58	SD 13.87 19.14 12.67 8.34 8.88 (P = 0.002 (P = 0.002 (P = 0.002) (P = 0.002) (Total 35 60 25 50 30 200 0, df = 4 2} nidine Total 40 60	Mean 130.22 106.09 119.28 118.2 129.1 (P < 0.0 Neb N Mean 119.4 104.69	SD 9.44 19.14 8.4 13.55 4.26 001); ² -	Total 35 60 25 50 30 200 85%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-6.04, 3.82]	IV, Random, 95% CI	100
	Hussain et al Misra et al Sheth et al Shrivastava et al Suryawanshi et al Total (95% CI) Heterogeneity: Tau ² - Test for overall effect <u>Study or Subgroup</u> Kalia et al Misra et al Suryawanshi et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16 Neb De Mean 98.9	SD 13.87 19.14 12.67 8.34 8.88 (P = 0.002 (P = 0.002 (P = 0.002) (P = 0.002) (Total 35 60 25 50 30 200 0, df = 4 2} nidine Total 40 60 30	Mean 130.22 106.09 119.28 118.2 129.1 (P < 0.0 Neb N Mean 119.4	SD 9.44 19.14 8.4 13.55 4.26 001); ² -	Total 35 60 25 50 30 200 85%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5% 35.6%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-8.04, 3.82] -10.10 [-13.80, -6.40]	IV, Random, 95% CI	100
	Hussain et al Misra et al Sheth et al Shrth et al Suryawanshi et al Total (95% Cl) Heterogenehy: Tau ² a Test for overall effect Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl)	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16 Neb De Mean 98.9 102.58 110.83	SD 13.87 19.14 12.67 8.34 8.88 Sh ² = 25.94 (P = 0.002 Exmedetom SD 15.94 13.64 8.89	Total 35 60 25 50 30 200 0, df = 4 2} nidine Total 40 60 30 130	Mean 130.22 106.09 119.28 118.2 129.1 (P < 0.0 Neb N Mean 119.4 104.69 120.93	SD 9.44 19.14 8.4 13.55 4.26 001); ² -	Total 35 60 25 50 30 200 85%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-6.04, 3.82]	IV, Random, 95% CI	100
	Hussain et al Misra et al Sheth et al Shrivastava et al Shrivastava et al Shrivastava et al Total (95% Cl) Heterogenetty: Tau ² - Test for overall effect Study or Subgroup Kalla et al Misra et al Surgawanshi et al Total (95% Cl) Heterogenetty: Tau ² -	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16 Neb De Mean 98.9 102.58 110.83 = 54.65; C	SD 13.87 19.14 12.67 8.34 8.88 ch ² = 25.94 (P = 0.002 (P	Total 35 60 25 500 30 200 0, df = 4 2} nidine Total 40 60 30 130 1, df = 2	Mean 130.22 106.09 119.28 118.2 129.1 (P < 0.0 Neb N Mean 119.4 104.69 120.93	SD 9.44 19.14 8.4 13.55 4.26 001); ² -	Total 35 60 25 50 30 200 85%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5% 35.6%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-8.04, 3.82] -10.10 [-13.80, -6.40]	IV, Random, 95% CI	100
	Hussain et al Misra et al Sheth et al Shrth et al Suryawanshi et al Total (95% Cl) Heterogenehy: Tau ² a Test for overall effect Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl)	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16 Neb De Mean 98.9 102.58 110.83 = 54.65; C	SD 13.87 19.14 12.67 8.34 8.88 ch ² = 25.94 (P = 0.002 (P	Total 35 60 25 500 30 200 0, df = 4 2} nidine Total 40 60 30 130 1, df = 2	Mean 130.22 106.09 119.28 118.2 129.1 (P < 0.0 Neb N Mean 119.4 104.69 120.93	SD 9.44 19.14 8.4 13.55 4.26 001); ² -	Total 35 60 25 50 30 200 85%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5% 35.6%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-8.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89]	IV, Random, 95% CI	
	Hussain et al Misra et al Sheth et al Shrivastava et al Shrivastava et al Shrivastava et al Total (95% Cl) Heterogenety: Tau ² - Test for overall effect Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² - Test for overall effect	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C z = 3.16 Neb De Mean 98.9 102.58 110.83 = 54.65; C z = 2.38 Neb De	SD 13.87 19.14 12.67 8.34 8.86 (P = 0.002 (P = 0.002 (P = 0.02) (P = 0.02) (P = 0.02) (P = 0.02) (P = 0.02)	Total 35 60 25 50 30 200 0, df = 4 2) nidine Total 40 60 30 1, df = 2	Mean 130.22 106.09 119.28 119.28 119.28 129.1 (P < 0.0 Neb N Mean 119.4 104.69 120.93 (P = 0.0 Neb N	SD 9.44 19.14 8.4 13.55 4.26 001); ² - 001); ² - 12.77 19.06 5.27 002); ² -	Total 35 60 25 50 30 200 85% line Total 40 60 30 130 88%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5% 35.6% 100.0%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-8.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference	IV, Random, 95% CI	
	Hussain et al Misra et al Sheth et al Shrth et al Shrth et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² + Test for overall effect Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² + Test for overall effect Study or Subgroup	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16 Neb De Mean 98.9 102.58 110.83 = 54.65; C : Z = 2.38	SD 13.87 19.14 12.67 8.34 8.88 Shi ² = 25.94 (P = 0.002 xmedetom SD 15.94 13.64 8.89 Shi ² = 17.33 (P = 0.02) xmedetom SD SD SD SD SD SD SD SD SD SD	Total 35 60 255 50 30 200 0, df = 4 2} nidine Total 40 60 30 130 1, df = 2	Mean 130.22 106.09 119.28 118.2 129.1 (P < 0.0 Neb N Mean 119.4 104.69 120.93 (P = 0.0 Neb N Mean	SD 9.44 19.14 8.4 13.55 4.26 0011; i ² - 0011; i ² - 0011; i ² - 12.77 19.06 5.27 002); i ² -	Total 35 60 250 30 200 85% Iline Total 40 60 30 130 88%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5% 100.0% Weight	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-5.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-8.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI	IV, Random, 95% CI	
	Hussain et al Misra et al Sheth et al Sheth et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² - Test for overall effect Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² - Test for overall effect Study or Subgroup Kalia et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C = Z = 3.16 Neb De Mean 98.9 102.58 110.83 = 54.65; C = Z = 2.38 Neb De	$\frac{SD}{13.87}$ 19.14 12.67 8.34 8.88 $hh^2 = 25.9t$ (P = 0.002 xmedetom SD 15.94 13.64 8.89 $hh^2 = 17.3$ (P = 0.02) xmedeton SD 13.56	Total 35 60 25 50 30 200 0, df = 4 2) nidine Total 40 60 30 1, df = 2	Mean 130.02 106.09 119.28 118.2 129.1 (P < 0.0 Neb N Mean 119.4 (P < 0.0 Neb N Mean 119.4 104.69 120.93 (P = 0.0 Neb N Mean 118.2 129.1 (P < 0.0 Neb N Mean 119.4 (P < 0.0 Neb N Mean 118.0 (P < 0.0 Neb N Mean (P < 0.0 Neb N (P < 0.0 Neb N (P < 0.0 Neb N (P < 0.0 (P <	SD 9.44 19.14 8.4 13.55 4.26 001); ^µ - 001); ^µ - 001); ^µ - 19.06 5.27 002); ^µ - 002); ^µ -	Total 35 60 25 50 30 200 85% line Total 40 60 30 130 88%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 35.6% 100.0% Weight 30.8%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-8.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI -12.00 [-17.82, -6.18]	IV, Random, 95% CI	
f) Effect on SBP at 6 minute	Hussain et al Misra et al Sheth et al Shrth et al Shrth et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² + Test for overall effect Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² + Test for overall effect Study or Subgroup	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C = Z = 3.16 Neb De Mean 98.9 102.58 110.83 = 54.65; C = Z = 2.38 Neb De Mean 106.05	SD 13.87 19.14 12.67 8.34 8.88 ht ² = 25.9((P = 0.002) ixmedetom 5.94 13.64 8.89 ht ² = 17.3 (P = 0.02) ixmedetom 5.94 13.56 13.56	Total 35 60 255 50 200 0, df = 4 2) nidine Total 40 60 30 130 1, df = 2 9	Mean 130.02 106.09 119.28 118.2 129.1 (P < 0.0 Neb N Mean 119.4 (P < 0.0 Neb N Mean 119.4 104.69 120.93 (P = 0.0 Neb N Mean 118.2 129.1 (P < 0.0 Neb N Mean 119.4 (P < 0.0 Neb N Mean 118.0 (P < 0.0 Neb N Mean (P < 0.0 Neb N (P < 0.0 Neb N (P < 0.0 Neb N (P < 0.0 (P <	SD 9.44 19.14 8.4 13.55 4.26 0011; ^p - 0011; ^p - SD 12.77 19.06 5.27 19.06 5.27 19.02; ^p - 13.04 13 13.64	Total 35 60 25 50 30 200 85% 100 85%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5% 35.6% 100.0% Weight 30.8% 27.0%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-5.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.150 [-26.83, -114.17] -2.11 [-6.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI -12.00 [-17.82, -6.18] -3.51 [-10.03, 3.01]	IV, Random, 95% CI	
f) Effect on SBP at 6 minute	Hussain et al Misra et al Sheth et al Shrthastava et al Suryawanshi et al Total (95% Cl) Heterogenetty: Tau ² - Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Total (95% Cl) Heterogenetty: Tau ² - Test for overall effect Study or Subgroup Kalla et al Misra et al Suryawanshi et al	Mean 122.57 103.61 111.2 109.86 110.9 = 35.55; C = Z = 3.16 Neb De Mean 98.9 102.58 110.83 = 54.65; C = Z = 2.38 Neb De Mean 106.05 100.12	SD 13.87 19.14 12.67 8.34 8.88 ht ² = 25.9((P = 0.002) ixmedetom 5.94 13.64 8.89 ht ² = 17.3 (P = 0.02) ixmedetom 5.94 13.56 13.56	Total 35 60 25 50 30 200 0, df = 4 2} nidine Total 40 60 30 130 1, df = 2 } nidine Total 40 60 30 30 30 20 20 20 20 20 20 20 20 20 20 20 20 20	Mean 130.22 106.09 119.28 118.2 129.1 (P < 0.0 Neb N Mean 119.4 120.93 (P = 0.0 Neb N Mean 118.05 103.63 117.83	SD 9.44 19.14 8.4 13.55 4.26 0011; ^p - 0011; ^p - SD 12.77 19.06 5.27 19.06 5.27 19.02; ^p - 13.04 13 13.64	Total 35 60 25 50 30 200 85% 100 85% 100 88%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5% 35.6% 100.0% Weight 30.8% 27.0% 42.2%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-5.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-5.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI -12.00 [-17.82, -6.18] -3.51 [-10.03, 3.01] -6.50 [-11.08, -2.72]	IV, Random, 95% CI	
f) Effect on SBP at 6 minute	Hussain et al Misra et al Sheth et al Sheth et al Shrivastava et al Suryawanshi et al Total (95% Cl) Heterogenehy: Tau ² - Test for overall effect Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenehy: Tau ² - Test for overall effect Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl)	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : 2 = 3.16 Neb De Mean 98.9 102.58 110.83 = 54.65; C : 2 = 2.38 Neb De Mean 106.05 100.12 110.93	$\frac{SD}{13.87}$ 19.14 12.67 8.34 12.67 8.38 (P = 0.002 xmedetom SD 15.94 13.94 13.94 13.94 13.94 13.94 13.94 13.56 21.85 9.34	Total 35 600 25 500 2000	Mean 130.22 106.09 119.28 119.28 129.1 (P < 0.0 Neb N Mean 119.4 120.93 (P = 0.0 Neb N Mean 118.05 103.63 117.83	SD 9.44 19.14 19.14 8.4 13.55 4.26 001); ² - 001); ² - 001); ² - 12.77 19.06 5.27 19.06 5.27 002); ² - 13.04 13.04 13.04 7.02	Total 35 60 25 50 30 200 • 85% Total 130 • 88%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5% 35.6% 100.0% Weight 30.8% 27.0%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-5.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-5.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI -12.00 [-17.82, -6.18] -3.51 [-10.03, 3.01] -6.50 [-11.08, -2.72]	IV, Random, 95% CI	100
f) Effect on SBP at 6 minute	Hussain et al Misra et al Sheth et al Shrthastava et al Suryawanshi et al Total (95% Cl) Heterogenetty: Tau ² - Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Total (95% Cl) Heterogenetty: Tau ² - Test for overall effect Study or Subgroup Kalla et al Misra et al Suryawanshi et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16 Mean 98.9 102.58 110.83 = 54.65; C : Z = 2.38 Neb De Mean 106.05 100.12 110.93 = 6.98; Ch	$\frac{SD}{13.87}$ 19.14 19.14 19.267 8.34 8.88 (P = 0.002 (P = 0.02) (P =	Total 35 600 25 500 2000 0, df = 4 2} idine Total 1300 1300 1300 1300 1300 1300 400 600 300 1300 1300 400 600 300 1300 1300 600 1300 600 1300 600 1000 10	Mean 130.22 106.09 119.28 119.28 129.1 (P < 0.0 Neb N Mean 119.4 120.93 (P = 0.0 Neb N Mean 118.05 103.63 117.83	SD 9.44 19.14 19.14 8.4 13.55 4.26 001); ² - 001); ² - 001); ² - 12.77 19.06 5.27 19.06 5.27 002); ² - 13.04 13.04 13.04 7.02	Total 35 60 25 50 30 200 • 85% Total 130 • 88%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5% 35.6% 100.0% Weight 30.8% 27.0% 42.2%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-5.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-5.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI -12.00 [-17.82, -6.18] -3.51 [-10.03, 3.01] -6.50 [-11.08, -2.72]	IV, Random, 95% CI	
f) Effect on SBP at 6 minute	Hussain et al Misra et al Sheth et al Shrivastava et al Shrivastava et al Shrivastava et al Shrivastava et al Shrivastava et al Study or Subgroup Kalia et al Misra et al Surgawanshi et al Total (95% Cl) Heterogenety: Tau ² - Test for overall effect Study or Subgroup Kalia et al Misra et al Surgawanshi et al Surgawanshi et al Surgawanshi et al Surgawanshi et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C = Z = 3.16 Neb De Mean 96.9 102.58 110.83 = 54.65; C = Z = 2.38 Neb De Mean 106.05 100.12 110.93 = 6.98; Ch	$ \begin{array}{c} \text{SD} \\ 13.87 \\ 19.14 \\ 12.67 \\ 8.34 \\ 8.88 \\ \text{(P} = 0.007 \\ \text{(P} = 0.007 \\ \text{(P} = 0.007 \\ 15.94 \\ 8.89 \\ 13.64 \\ 8.89 \\ \text{(P} = 0.02) \\ \text{exmedeton} \\ \text{SD} \\ \text{(P} = 0.02) \\ \text{exmedeton} \\ \text{SD} \\ \text{(P} = 0.02) \\ \text{exmedeton} \\ \text{SD} \\ \text{(P} = 0.02) \\ \text{(P} = 0.02) \\ \text{(P} = 0.02) \\ \text{(P} = 0.02) \\ \text{(P} = 0.001 \\ \text{(P}$	Total 35 60 25 50 0 200 200 200 200 200 200 200 20	Mean 130.22 106.09 119.28 129.1 (P < 0.0 Neb N Mean 119.4 (P < 0.0 Neb N Mean 119.4 (P = 0.0 Neb N Mean 119.7 (P < 0.0 Neb N Mean 110.7 (P < 0.0 Neb N Neb N Neb N Neb N Neb N Neb N Neb Neb Neb Neb Neb Neb Neb Neb Neb Neb	SD 9.44 8.4 13.55 4.26 0001); ⁴ - 0001); ⁴ - 0001); ⁴ - 0001; ⁴ - 12.77 19.06 5.27 19.06 5.27 13.64 7.62 13.74 13.64 7.62	Total 355 60 25 50 200 • 85% iine Total 40 60 30 130 • 85% iine Total 130 • 85%	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5% 35.6% 100.0% Weight 30.8% 27.0% 42.2%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-8.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI -3.51 [-10.03, 3.01] -6.90 [-11.08, -2.72] -7.56 [-11.88, -3.23]	IV, Random, 95% CI	100
f) Effect on SBP at 6 minute	Hussain et al Misra et al Sheth et al Shrivastava et al Shrivastava et al Shrivastava et al Shrivastava et al Shrivastava et al Study or Subgroup Kalia et al Misra et al Surgawanshi et al Total (95% Cl) Heterogenety: Tau ² - Test for overall effect Study or Subgroup Kalia et al Misra et al Surgawanshi et al Surgawanshi et al Surgawanshi et al Surgawanshi et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C = Z = 3.16 Neb De Mean 96.9 102.58 110.83 = 54.65; C = Z = 2.38 Neb De Mean 106.05 100.12 110.93 = 6.98; Ch	$\frac{SD}{13.87}$ 19.14 19.14 12.67 8.34 8.88 (P = 0.002 (P = 0.02) (P =	Total 35 60 25 50 0 200 200 200 200 200 200 200 20	Меал 130.22 106.09 119.28 129.1 (₽ < 0.0 Neb N Mean 119.4 (₽ < 0.0 Neb N Mean 119.4 (₽ = 0.0 116.05 110.65 110.65 110.65 110.65 110.65 110.65 110.65 110.65 110.65 110.65 110.65 110.65 100.55 100.55 100.55 100.55 100.5	SD 9.44 8.4 13.55 4.26 0001; ² - 12.77 19.06 5.27 0002; ³ - 13.13.64 13.13.64 13.13.64 13.13.64 13.13.64 13.13.64 13.13.64 13.13.64 13.13.64 13.13.14 13.14 13.14 13.14 13.14 13.14 13.14 13.14 13.14 13.14 13.14 13.14 13.14 13.14 13.14 13.14 13.14 13.15 13.14 13.15 13.14 13.15 13.14 13.15 13.15 13.14 13.15 13.15 13.14 13.15 13	Total 35 60 25 50 200 200 200 200 200 200	19.7% 18.0% 19.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5% 35.6% 100.0% Weight 30.8% 27.0% 42.2%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-5.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-5.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI -12.00 [-17.82, -6.18] -3.51 [-10.03, 3.01] -5.90 [-11.08, -2.72] -7.56 [-11.88, -3.23] Mean Difference	IV, Random, 95% CI	100
f) Effect on SBP at 6 minute g) Effect on SBP at 8 minute	Hussain et al Misra et al Sheth et al Sheth et al Shrih et al Shrih et al Total (95% Cl) Heterogeneity: Tau ² - Test for overall effect Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² - Test for overall effect Study or Subgroup Kalia et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² - Test for overall effect Study or Subgroup Kalia et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16 Mean 98.9 102.58 110.83 = 54.65; C : Z = 2.38 Neb De Mean 106.05 100.12 110.93 = 6.98; Ch : Z = 3.43 Neb De Mean 112.2	$ \begin{array}{c} \text{SD} \\ 13.87 \\ 19.14 \\ 12.67 \\ 8.34 \\ 8.88 \\ \text{(}P = 0.002 \\ \text{(}P = 0.002 \\ \text{(}P = 0.02) \\ \text{(}P = 0.00) \\ \text{(}P = $	Total 355 600 2000 2000 300, df = 4 400 600 300 1, df = 2 1300 1300 1300 1300 1300 1300 1400 400 400 400 400 400 400 41	Mean 130.22 106.09 119.28 129.1 (P < 0.0 Neb N Mean 119.4 (P < 0.0 Neb N Mean 119.4 (P < 0.0 Neb N Mean 110.4 69 120.93 (P = 0.0 Neb N Mean 118.2 104.69 120.32 (P < 0.0 Neb N Mean 119.4 (P < 0.0 Neb N Mean 110.4 (P) (P < 0.0 Neb N Mean 110.4 (P) (P)	SD SD 9.44 19.14 19.14 8.4 13.55 4.26 ormal Sa SD 12.77 19.06 5.27 50 002); t ² - - ormal Sa SD 13.35 13.64 7.02 ; t ² = 483 4ormal S 13.36 13 13.64 7.02 : 13.65	Total 355 60 25 50 200 200 200 200 200 200 200 200	19.7% 18.0% 21.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5% 35.6% 100.0% Weight 30.6% 27.0% 42.2% 100.0%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-5.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -8.26 [-12.75, -3.93] -8.26 [-12.75, -3.93] -8.27, -3.93] -8.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.10 [-13.80, -6.40] -10.10 [-13.80, -6.40] -10.20 [-7.82, -6.16] -3.51 [-10.03, 3.01] -6.90 [-11.08, -2.72] -7.56 [-11.88, -3.23] Mean Difference IV, Random, 95% CI -5.99, -0.01]	IV, Random, 95% CI	100
f) Effect on SBP at 6 minute	Hussain et al Misra et al Sheth et al Sheth et al Shrth et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² , Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² , Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² , Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Suryawanshi et al Suryawanshi et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16 Mean 98.9 102.58 110.83 = 54.65; C : Z = 2.38 Neb De Mean 106.05 100.12 110.93 = 6.98; Ch : Z = 3.43 Neb Do Mean 112.2 110.93	$\frac{SD}{13.87}$ 13.87 19.14 12.67 8.34 8.88 ($P = 0.002$ xmedetom SD 15.94 13.64 13.64 13.64 8.89 ($P = 0.022$ xmedetom SD 13.59 13.59 13.56 9.34 P = 0.022 xmedetom SD 13.56	Total 355 600 255 500 300 2000 2000 2000 2000 2000	Mean 130.22 106.09 119.28 129.1 (₽ < 0.0 Neb N Mean 119.4 (₽ < 0.0 Neb N Mean 119.4 (₽ = 0.0 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 110.69 103.63 110.69 103.63 103.63 103.63 103.63 103.63 103.63 103.63 103.63 103.63 103.63 103.63 103.63 103.63 105.09 100 105.09 10	SD 9.44 19.14 8.4 13.55 50 12.77 50 12.77 50 12.77 50 12.77 50 13.64 7.02 13.64 7.02 13.64 7.02 13.64 7.02	Total 355 60 25 50 200 200 200 200 200 200	19.7% 18.0% 18.0% 18.0% 21.1% 22.1% 100.0% Weight 33.5% 100.0% Weight 33.5% 100.0% 100.0%	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-5.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -8.26 [-12.75, -3.93] -8.26 [-12.75, -3.93] -8.26 [-12.75, -3.93] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-8.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI -3.51 [-10.03, 3.01] -6.90 [-11.08, -2.72] -7.56 [-11.88, -3.23] Mean Difference IV, Random, 95% CI -5.50 [-5.99, -0.01] -4.22 [-0.05, 2.13]	IV, Random, 95% CI	100
f) Effect on SBP at 6 minute g) Effect on SBP at 8 minute	Hussain et al Misra et al Sheth et al Sheth et al Shrivastava et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² - Test for overall effect Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² - Test for overall effect Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² - Test for overall effect Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogeneity: Tau ² - Test for overall effect Study or Subgroup Kalla et al Misra et al Study or Subgroup Kalla et al Misra et al Sheth et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C = Z = 3.16 Neb De Mean 96.9 102.58 110.83 = 54.65; C = Z = 2.38 Neb De Mean 106.05 100.12 110.93 = 6.98; Ch = 2 = 3.43 Neb De Mean 112.2 99.41 107.76	$ \begin{array}{c} \text{SD} \\ \textbf{13.87} \\ \textbf{19.14} \\ \textbf{19.14} \\ \textbf{12.67} \\ \textbf{8.34} \\ \textbf{8.88} \\ \textbf{(P=0.002)} \\ \textbf{(P=0.002)} \\ \textbf{xmedetom} \\ \textbf{SD} \\ \textbf{15.94} \\ \textbf{13.64} \\ \textbf{8.89} \\ \textbf{(P=0.02)} \\ \textbf{xmedetom} \\ \textbf{SD} \\ \textbf{xmedetom} \\ \textbf{SD} \\ \textbf{xmedetom} \\ \textbf{SD} \\ \textbf{13.56} \\ \textbf{9.34} \\ \textbf{17-3.81,} \\ \textbf{(P=0.00)} \\ \textbf{xmedetom} \\ \textbf{SD} \\ \textbf{11.4} \\ \textbf{17.75} \\ \textbf{12.69} \\ \textbf{12.69} \end{array} $	Total 35 60 2000 25 30 2000 2000 30 2000 30 300 40 40 60 600 1300 1300 1300 1300 1300 1300 1300 1300 60 60 60 60 60 1300 1300 1300 1300 140 60 414 61 62 21	Mean 130.22 106.09 119.28 129.1 (P < 0.0 Neb N Mean 119.4 104.69 120.93 (P = 0.0 Neb N Mean 118.0 103.63 117.83 Neb N Mean 118.0 103.63 117.83 118.0 103.63 117.83 118.0 119.7 1119.7 119.	SD 9.44 19.14 8.4 8.4 8.4 8.4 13.55 4.26 0001); P - 13.55 4.26 0001); P - 12.77 19.06 5.27 0002); P - 19.06 5.27 0002); P - 13.35 13.64 7.02 13.35 13.64 7.02 13.55 13.64 13.65 15.67	Total 355 60 255 30 200 85% 11ine Total 40 60 30 130 - 88% 40 60 30 30 130 - 88% 40 60 30 30 130 40 60 60 60 25 20 200 200 200 200 200 200 200 200	19.7% 18.0% 19.1% 21.1% 21.1% 22.1% 100.0% Weight 31.9% 32.5% 32.5% 32.5% 32.5% 100.0% Weight 100.0% Weight 100.0% 1	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-8.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI -3.51 [-10.03, 3.01] -6.90 [-11.08, -2.72] -7.56 [-11.88, -3.23] Mean Difference IV, Random, 95% CI -5.00 [-9.99, -0.01] (-4.22 [-10.55, 1.21]	IV, Random, 95% CI	100
f) Effect on SBP at 6 minute g) Effect on SBP at 8 minute	Hussain et al Misra et al Sheth et al Sheth et al Shrth et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² A Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² A Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Suryawanshi et al Total (95% Cl) Heterogenety: Tau ² A Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Suryawanshi et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16 Mean 98.9 102.58 110.83 = 54.65; C : Z = 2.38 Neb De Mean 106.05 100.12 110.93 = 6.98; Ch : Z = 3.43 Neb Do Mean 112.2 110.93		Total 355 600 2000 2550 300 2000 2000 2000 2000 2010 301 301 301 301 301 301 301 301 301 301 301 301 <	Mean 130.22 106.09 119.28 129.1 (₽ < 0.0 Neb N Mean 119.4 (₽ < 0.0 Neb N Mean 119.4 (₽ = 0.0 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 110.69 103.63 110.69 103.63 103.63 103.63 103.63 103.63 103.63 103.63 103.63 103.63 103.63 103.63 103.63 103.63 105.09 100 105.09 10	SD 9.44 19.14 8.4 8.4 8.4 9.001); H 4.26 0001); H 4.26 9.001); H 4.26 9.001]; H 4.26 9.001]; H 4.26 9.001]; H 4.26 9.001]; H 4	Total 355 60 255 50 0 200 - 85% 1ine Total 40 60 30 130 - 88% 40 60 30 130 - 88%	19.7% 18.0% 18.0% 19.1% 21.1% 21.1% 22.1% 100.0% Weight 33.9% 32.5% 35.6% 100.0% Weight 30.6% 100.0% 1	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-5.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-5.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI -3.51 [-10.03, 3.01] -5.90 [-11.08, -2.72] -7.56 [-11.88, -3.23] Mean Difference IV, Random, 95% CI (-5.00 [-9.39, -0.01] (-4.22 [-10.57, 2.13] (-4.72 [-10.652, -1.38]	IV, Random, 95% CI	100
f) Effect on SBP at 6 minute g) Effect on SBP at 8 minute	Hussain et al Misra et al Sheth et al Sheth et al Sheth et al Sheth et al Sheth et al Sheth et al Total (95% CI) Heterogenetty: Tau ² - Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Total (95% CI) Heterogenetty: Tau ² - Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Total (95% CI) Heterogenetty: Tau ² - Test for overall effect Study or Subgroup Kalla et al Sheth et al Sheth et al Sheth et al Sheth et al Sheth et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16 Mean 98.9 102.58 110.83 = 54.65; C : Z = 2.38 Neb De Mean 106.05 100.12 110.93 = 6.98; Ch : Z = 3.43 Neb Do Mean 102.57 100.58 = 3.43 Neb Do Mean 107.76 114.24 114.24 114.24 114.24 114.25 114.24 114.25 114.24 114.25 114.24 114.25 114.25 114.24 114.25 114.		Total 355 600 2000 2000 300 2000 300 2000 300	Mean 130.22 106.09 119.28 129.1 (P < 0.0 Neb N Mean 119.4 (P < 0.0 Neb N Mean 119.2 (P < 0.0 Neb N Mean 119.2 (P < 0.0 Neb N Mean 119.2 (P < 0.0 Neb N Mean 119.4 (P < 0.0 Neb N Mean 110.4 (P < 0.0 Neb N Mean 110.4 (P < 0.0 Neb N Mean 110.4 (P < 0.0 Neb N Mean 111.4 (P < 0.0 Nean 111.4 (P < 0.0 Nean 111.4 (P < 0.0 Nean 111.4 (P < 0.0 Nean 111.4 (P < 0.0 Nean 111.4 (P < 0.0 Nean 111.4 (P < 0.0 Nean 11.4 (P < 0	SD 9.44 19.14 8.4 8.4 8.4 9.001); H 4.26 0001); H 4.26 9.001); H 4.26 9.001]; H 4.26 9.001]; H 4.26 9.001]; H 4.26 9.001]; H 4	Total 35 60 250 30 200 85% 100 88% 1100 88% 1100 60 30 130 60 30 130 60 30 130 60 30 30 130 60 30 30 30 30 200 80%	19.7% 18.0% 18.0% 19.1% 21.1% 21.1% 22.1% 100.0% Weight 33.9% 32.5% 33.5% 100.0% Weight 33.5% 100.0% Weight 100.0% 1	IV, Random, 95% CI -7.65 [-13.21, 2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-5.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI -3.51 [-10.03, 3.01] -5.90 [-11.08, -2.72] -7.56 [-11.88, -3.23] Mean Difference IV, Random, 95% CI 6 -5.00 [-9.99, -0.01] 6 -4.22 [-10.57, 2.13] -4.72 [-10.52, -1.58] 6 -5.36 [-9.59, -1.13]	IV, Random, 95% CI	100
f) Effect on SBP at 6 minute g) Effect on SBP at 8 minute	Hussain et al Misra et al Sheth et al Sheth et al Shrthet al Shrthestava et al Suryawanshi et al Total (95% Cl) Heterogenehy: Tau ² - Test for overall effect Study or Subgroup Kalla et al Misra et al Suryawanshi et al Total (95% Cl) Heterogenehy: Tau ² - Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Total (95% Cl) Heterogenehy: Tau ² - Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Suryawanshi et al Study or Subgroup Kalla et al Misra et al Shrhet et al Shrhet et al Suryawanshi et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16 Mean 98.9 102.58 110.83 = 54.65; C : Z = 2.38 Neb De Mean 106.05 100.12 110.93 = 6.98; Cf: : Z = 3.43 Neb De Mean 106.05 100.12 110.93	$\frac{SD}{13.87}$ 13.87 19.14 12.67 8.86 (h ² = 25.94 (P = 0.002) xmedetom SD 13.59 13.59 13.59 13.56 13.56 21.85 9.34 xmedetom SD 13.56 13.56 13.56 13.56 13.56 9.34 xmedetom SD SD 13.56 9.34 xmedetom SD SD SD SD SD SD SD SD SD SD	Total 355 600 25500 300 2000 2000 2000 2000 2000 2000 300 2000 1300 1300 1300 1300 1300 1300 660 300 1300 1300 600 300 midine Total 1300 600 300 3100 21300 2000 3100 2010	Mean 130.22 106.09 119.28 129.1 (₽ < 0.0 Neb N Mean 119.4 (₽ < 0.0 Neb N Mean 119.4 (₽ = 0.0 S 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.	SD 9.44 41 84 4.26 0001); ¹ - 4.26 50 12.77 50 12.77 50 12.77 50 12.77 50 13.64 7.02 50 13.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 51.55 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 5	Total 35 60 200 2550 30 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 130 400 60 30 130 400 60 30 130 400 60 30 130 400 60 30 30 30 30 30 30 30 30 30 30 30 30 3	19.7% 18.0% 18.0% 19.1% 21.1% 21.1% 22.1% 100.0% Weight 33.9% 32.5% 33.5% 100.0% Weight 33.5% 100.0% Weight 100.0% 1	IV, Random, 95% CI -7.65 [-13.21, -2.09] -2.28 [-5.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-5.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI -3.51 [-10.03, 3.01] -5.90 [-11.08, -2.72] -7.56 [-11.88, -3.23] Mean Difference IV, Random, 95% CI (-5.00 [-9.39, -0.01] (-4.22 [-10.57, 2.13] (-4.72 [-10.652, -1.38]	IV, Random, 95% CI	100
f) Effect on SBP at 6 minute g) Effect on SBP at 8 minute	Hussain et al Misra et al Sheth et al Sheth et al Sheth et al Sheth et al Sheth et al Sheth et al Total (95% CI) Heterogenetty: Tau ² - Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Total (95% CI) Heterogenetty: Tau ² - Test for overall effect Study or Subgroup Kalla et al Suryawanshi et al Total (95% CI) Heterogenetty: Tau ² - Test for overall effect Study or Subgroup Kalla et al Sheth et al Sheth et al Sheth et al Sheth et al Sheth et al	Mean 122.57 103.81 111.2 109.86 110.9 = 35.55; C : Z = 3.16 Mean 98.9 102.58 110.83 = 54.65; C : Z = 2.38 Neb De Mean 106.05 100.12 110.93 = 6.98; Ch : Z = 3.43 Neb De Mean 112.2 99.41 110.7 = 0.00; Ch	$ \begin{array}{c} \text{SD} \\ 13.87 \\ 19.14 \\ 12.67 \\ 8.34 \\ 8.88 \\ \text{(}P = 0.002 \\ \text{(}P = 0.002 \\ \text{(}P = 0.002 \\ \text{(}P = 0.023 \\ \text{(}P = $	Total 355 600 2000 2000 300, df = 4 20	Mean 130.22 106.09 119.28 129.1 (₽ < 0.0 Neb N Mean 119.4 (₽ < 0.0 Neb N Mean 119.4 (₽ = 0.0 S 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.63 103.63 117.	SD 9.44 41 84 4.26 0001); ¹ - 4.26 50 12.77 50 12.77 50 12.77 50 12.77 50 13.64 7.02 50 13.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 7.02 51.3.64 51.55 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 51.56 51.57 5	Total 35 60 200 2550 30 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 130 400 60 30 130 400 60 30 130 400 60 30 130 400 60 30 30 30 30 30 30 30 30 30 30 30 30 3	19.7% 18.0% 18.0% 19.1% 21.1% 21.1% 22.1% 100.0% Weight 33.9% 32.5% 33.5% 100.0% Weight 33.5% 100.0% Weight 100.0% 1	IV, Random, 95% CI -7.65 [-13.21, 2.09] -2.28 [-9.13, 4.57] -8.08 [-14.04, -2.12] -8.34 [-12.75, -3.93] -18.20 [-21.75, -3.93] -18.20 [-21.72, -14.68] -9.25 [-14.99, -3.51] Mean Difference IV, Random, 95% CI -20.50 [-26.83, -14.17] -2.11 [-5.04, 3.82] -10.10 [-13.80, -6.40] -10.82 [-19.74, -1.89] Mean Difference IV, Random, 95% CI -3.51 [-10.03, 3.01] -5.90 [-11.08, -2.72] -7.56 [-11.88, -3.23] Mean Difference IV, Random, 95% CI 6 -5.00 [-9.99, -0.01] 6 -4.22 [-10.57, 2.13] -4.72 [-10.52, -1.58] 6 -5.36 [-9.59, -1.13]	IV, Random, 95% CI	100

Fig. 3 Effect of nebulized dexmedetomidine on systolic blood pressure

describe lottery method to randomly allocate the groups which is not considered the recommended method of randomization [18]. Information about allocation concealment was only mentioned by Misra et al. and Shrivastava et al. and were considered as low risk, rest all studies were considered at either high or unclear risk for bias arising from the randomization process [12, 19]. The blinding of the participants and personnel was done in all the studies (double blinded), except Sheth et al. which was judged to be at unclear risk of bias due to deviation

Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI IV, Random, 95% CI a) Effect on DBP at 1 minute Hussain et al 86.88 14 35 93.17 11.82 35 22.4% -6.29 -12.36, -0.22] -+ Sheth et al 76.48 7.48 25 84.96 4.24 25 26.0% -6.48 [-11.85, -5.11] + Sheth et al 73.72 10.98 50.7 91.8 9.92 50 25.2% -5.46 [-5.6, -1.36] + Suryawanshi et al 73.72 10.98 50.2 6.74 30 26.4% -18.14 [-21.18, -15.10] + Total (95% CI) 140 100.0% -9.78 [-16.23, -3.32] + -	
a) Effect on DBP at 1 minute Sheth et al 76.48 7.48 25 84.96 4.24 25 26.0% -8.48 [-11.85, -5.11] * Shrbastava et al 73.72 10.98 50 79.18 9.92 50 25.2% -5.46 [-9.56, -1.36] * Suryawanshi et al 72.06 5.15 30 90.2 6.74 30 26.4% -18.14 [-21.18, -15.10] * Total (95% CI) 140 100.0% -9.78 [-16.23, -3.32] * Heterogenety: Tau ² = 38.70; Ch ² = 32.60, df = 3 (P < 0.00001); r ² = 91%	
a) Enert on bbr at 1 minute Shrbastava et al 73.72 10.98 50 79.18 9.92 50 25.2% -5.46 -9.56, -1.36	
Shrbvastava et al 73.72 10.98 50 79.18 9.92 50 25.2% -5.46 [-9.56, -1.36] Suryawanshi et al 72.06 5.15 30 90.2 6.74 30 26.4% -18.14 [-21.18, -15.10] Total (95% CI) 140 100.0% -9.78 [-16.23, -3.32] \blacklozenge Heterogenety: Tau ² = 38.70; Ch ² = 32.60, df = 3 ($P < 0.00001$); $t^2 = 91\%$ $= 100$ $= 100$ $= 100$ $= 50$ $= 50$ $= 100$	
Total (95% Cl) 140 140 100.0% $-9.78 [-16.23, -3.32]$ Heterogenety: Tau ² = 38.70; Chi ² = 32.60, df = 3 ($P < 0.00001$); $r^2 = 91\%$	
Heterogeneity: Tau ² = 38.70; Ch ² = 32.60, df = 3 ($P < 0.00001$); $P = 91\%$	
	100
Test for overall effect: Z = 2.97 (P = 0.003) Favours [control] Favours [control]	.00
Neb Dexmedetomidine Neb Normal Saline Mean Difference Mean Difference	
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI IV, Random, 95% CI	
b) Effect on DBP at 2 minute Hussaln et al 89.08 14.01 35 97.11 10.7 35 30.9% -8.03 [-13.87, -2.19]	_
Kalla et al 61.15 9.88 40 75.2 11.03 40 33.2% -14.05 [-18.64, -9.46]	
Survawanshi et al 71.96 5.1 30 93.06 5.87 30 36.0% -21.10 [-23.88, -18.32]	
Total (95% Cl) 105 105 100.0% -14.73 [-22.30, -7.15]	
U_{2}	
	100
Favours [experimental] Favours [control]	
Neb Dexmedetomidine Neb Normal Saline Mean Difference Mean Difference	\dashv
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Fixed, 95% CI IV, Fixed, 95% CI	
Hussain et al 84.88 14.03 35 90.22 9.44 35 9.4% -5.34 [-10.94, 0.26]	
Sheth et al 73.44 6.96 25 78.08 4.12 25 29.4% -4.64 [-7.81, -1.47] =	
c) Effect on DBP at 5 minute Shrivastava et al 71.62 9.93 50 77.48 10.59 50 18.3% -5.86 (-9.88, -1.84)	
Suryawanshi et al 71.9 5.54 30 85.73 4.82 30 42.9% -13.83 [-16.46, -11.20]	
Total (95% CI) 140 140 100.0% -8.87 [-10.59, -7.15]	
	100
Favours [experimental] Favours [control]	
Neb Dexmedetomidine Neb Normal Saline Mean Difference Mean Difference	-
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI IV, Random, 95% CI	
Katla et al 70.33 11.1 40 72.68 10.73 40 13.3% -2.35 [-7.13, 2.43]	_
d) Effect on DBP at 10 minute Sherh et al 71.28 6.68 25 77.28 3.96 25 32.9% -6.00 [-9.04, -2.96] =	
Shrivastava et al 76.1 8.01 50 81.38 11.36 50 20.5% -5.28 [-9.13, -1.43]	
Survawanshi et al 73.03 6.86 30 77.56 4.94 30 33.3% -4.53 [-7.56, -1.50]	
Total (95% Cl) 145 145 100.0% -4.88 [-6.62, -3.13]	
Heterogeneity: $Tau^2 = 0.00$; Chi ² = 1.69, df = 3 (P = 0.64); P = 0%	100
Test for overall effect: Z = 5.48 (P < 0.00001) Favours (experimental) Favours (control)	.00
ravous (experimental) ravous (control)	

Fig. 4 Effect of nebulized dexmedetomidine on DBP

		Neb Dex	medetomi	dine	Neb No	ormal Sa	line		Mean Difference	Mean Difference	
	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	IV, Random, 95% CI	I
	Hussain et al	100.22	14.16	35	104.4	11.77	35	23.1%	-4.18 [-10.28, 1.92]		
 a) Effect on MBP at 1 minute 	Sheth et al	89.28	9.03	25	98.29	5.09	25	25.5%	-9.01 [-13.07, -4.95]	+	I
	Shrivastava et al	86.8	11.86	50	94.82		50	25.0%	-8.02 [-12.51, -3.53]		I
	Suryawanshi et al	85.86	5.77	30	105.58	6.6	30	26.4%	-19.72 [-22.86, -16.58]	•	I
	Total (95% CI)			140			140	100.0%	-10.47 [-17.66, -3.28]		I
	Heterogeneity: Tau ² =	48 52· Ch	P = 34 05		(P < 0.0)	10011-12		20010/0	10111 (11100, 5120)	· · · · · · · · · · · · · · · · · · ·	I
	Test for overall effect:				(· · · · · · ·		- 01/1			-100 -50 0 50	100
				·						Favours [experimental] Favours [control]	
		Neb Dex	medetomi	dine	Neb No	ormal Sa	line		Mean Difference	Mean Difference	_
	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	IV, Random, 95% CI	I
	Hussain et al	102.57	14.02	35	108.62	10.14	35	31.7%	-6.05 [-11.78, -0.32]		
b) Effect on MBP at 2 minute	Kalla et al	75.3	9.87	40	91.6	9.54	40	33.5%	-16.30 [-20.55, -12.05]	+	I
	Suryawanshi et al	85.41	5.73	30	108.86	5.83	30	34.6%	-23.45 [-26.38, -20.52]	•	I
	Tatal (05% CI)			105			105	100.00	15541 2400 610		
	Total (95% CI)			105				100.0%	-15.54 [-24.88, -6.19]	· · · ·	
	Heterogeneity: Tau ² =				(P < 0.00)001}; P	= 93%			-100 -50 0 50	100
	Test for overall effect:	2 = 3.26 (P = 0.001)	•						Favours [experimental] Favours [control]	
	[Neb Dex	medetomi	dine	Neb No	ormal Sa	line		Mean Difference	Mean Difference	
	Study or Subgroup	Mean	SD	Total	Mean	SD		Weight	IV, Random, 95% C		I
	Hussain et al	98.22	14.17	35	101.45	8.93	35	22.6%	-3.23 [-8.78, 2.32]		
c) Effect on MBP at 5 minute	Sheth et al	86.02	8.69	25	93.78	5.16	25	25.2%	-7.76 [-11.72, -3.80]		I
c) Effect of MDF at 5 minute	Shrivastava et al	84.44	8.97	50			50	25.1%	-5.74 [-9.73, -1.75]		I
	Suryawanshi et al	84.91	6.01	30	100.18	3.73	30	27.1%	-15.27 [-17.80, -12.74]	•	I
	Total (95% CI)			140			140	100.0%	-8.26 [-14.05, -2.47]		
	Heterogeneity: Tau ² =	20 E4. Ch	4 - 27 64		(n < 0 0)			100.0%	-8.20 [-14.03, -2.47]		
	Test for overall effect:				(P < 0.00	1001); F	- 097			-100 -50 0 50	100
	rest for overall effect.	2 - 2.00 \	r – 0.003	·						Favours [experimental] Favours [control]	
		Neb De	xmedeton	nidine	Neb N	lormal S	aline		Mean Difference	Mean Difference	
	Study or Subgroup	Mean	SD	Tota				Weight	t IV, Random, 95% CI	IV, Random, 95% CI	I
	Kaila et al	85.95	9.73	40	87.7	8.94	40	20.78	-1.75 [-5.84, 2.34]		
d) Effect on MBP at 10 minute	Sheth et al	83.44	8.5	25			25		-5.57 [-9.44, -1.70]	-	I
a, Encor on mor at 10 minute	Shrivastava et al	88.72	7.44	50		11.87	50		4 -4.80 [-8.68, -0.92]	-	I
	Suryawanshi et al	85.58	7.23	30	89.73	5.41	30		4-4.15 [-7.38, -0.92]	-	I
	Tabal (05% CI)							100.00	4121 500 227		
	Total (95% CI)			145				100.0%	6 -4.13 [-5.99, -2.27]	•	
	Heterogeneity: Tau ²				P = 0.58	; r = 07	6			-100 -50 0 50	100
	Test for overall effect	z = 4.35	(P < 0.00	01)						Favours [experimental] Favours [control]	
Remino	ders										

Fig. 5 Effect of nebulized dexmedetomidine on MBP




Fig. 6 RoB2 assessment in various domains

from the intended interventions (Fig. 4) [17]. Except for Misra et al. and Shrivastava et al., none of the included studies provided trial registration number and were considered to have unclear risk of bias in selection of reported results [12, 19].

Sensitivity analysis

Sensitivity analysis was performed after excluding Hussain et al. as this study differed from other RCTs in terms of dose of nebulized dexmedetomidine [16]. The dose used was 2 μ g /kg dexmedetomidine whereas in other studies the dose used was 1 μ g/kg dexmedetomidine, without any other methodological differences. Exclusion was not associated with any major change in heterogeneity or the effect estimate. The results of sensitivity analysis have been summarized in Supplementary files 2 and 3. **Publication bias assessment**

Funnel plots was plotted to assess for publication bias for the primary outcome effect on HR at 1 min for the studies included (Supplementary file 4). The publication bias is towards the studies with reduction in the hemodynamic response with nebulized dexmedetomidine.

Strength of evidence

GRADE assessment revealed very low quality evidence for effect of nebulized dexmedetomidine in reducing HR and SBP response to endotracheal intubation at 1, 2 and 5 min (Table 2).

Discussion

The findings of this SRMA suggests that premedication with dexmedetomidine nebulization significantly attenuates the hemodynamic response to laryngoscopy and ETI in comparison to normal saline nebulization. Laryngoscopy and ETI are associated with sympathetic stimulation leading to various hemodynamic changes like tachycardia, hypertension and increase in intracranial pressure which could be life threatening in patients with underlying cardio- or cerebro-vascular comorbidities [24]. The nebulized dexmedetomidine was found to reduce the mean HR as compared to normal saline at all the time points included (1, 2, 3, 4, 5, 6, 8, 10 min). Similar reduction was seen in SBP, DBP and MBP. However, the heterogeneity was found to be high across the studies. In sync with our findings, a recent RCT also found nebulized dexmedetomidine to effectively blunt the pressor response to laryngoscopy and ETI, better than that of nebulized fentanyl and equivalent to that of nebulized magnesium sulphate [25]. Dexmedetomidine's highlyselective agonistic action on presynaptic α 2-adrenergic receptors and subsequent inhibition of norepinephrine release from the locus coeruleus has been hypothesized as the most putative mechanism for its hemodynamic stress response attenuating action [26]. Intravenous dexmedetomidine also attenuates the hemodynamic responses to laryngoscopy and ETI but is associated with risk of bradycardia, hypotension and cardiac arrests [4, 9,

Certainty a	Certainty assessment						Nº of patients		Effect		Certainty	Importance
Nº of studies	Study design	Risk of bias	Risk of bias Inconsistency	Indirectness	Imprecision	Other considerations	dexmedetomidine nebulization	placebo or no intervention	Relative (95% Cl)	Absolute (95% CI)		
HR at 1 min 5	 HR at 1 min (assessed with: beats per minute) Fandomised Serious^a trials 	eats per minute Serious ^a	erious	not serious	not serious	publication bias strongly suspected	5	200		MD 8.59 beats/min lower (16.42 lower to 0.75 lower)	#OOO	There is very low quality evidence that preopera- tive nebulized dexme- detomidine compared in reducing HR response to endotra-
												cheal intuba- tion at 1 min.
HR at 2 min 4	HR at 2 min (assessed with: beats per minute) 4 randomised Serious ^a trials	eats per minute Serious ^a	serious ^b	not serious	not serious	publication bias strongly suspected	165	165		MD 13.48 beats/min lower (21.03 lower to 5.94 lower)	#000 Very low	There is very evoluting evoluting that preopera- tive nebulized dexme- detomidine compared is effective in reducing HR response HR response to endotra- tho at 2 min.

Table 2 GRADE assessment. Question: Is nebulized dexmedetomidine effective in blunting hemodynamic response to endotracheal intubation? Setting: Adult patients

Certainty assessment Nº of Study studies design	ssessment Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	№ of patients dexmedetomidine nebulization	placebo or no intervention	Effect Relative (95% CI)	Absolute (95% CI)	Certainty	Certainty Importance
HR at 5 min	HR at 5 min (assessed with: beats/minute)	eats/minute)										
N	randomised Serious ^a trials	Serious ^a	serious ^b	not serious	not serious	publication bias strongly suspected	200	500		MD 7.16 beats/min lower (12.49 lower to 1.83 lower)	000 Very low	There is very low quality evidence that preopera- tive nebulized dexme- detomidine compared is effective in reducing HR response to endotra- cheal intuba- tion at 5 min.
'n	5 randomised Serious ^a trials	Serious	serious ^b	not serious	not serious	publication bias strongly suspected	200	500		MD 1 2.48 mmHg lower (19.85 lower to 5.1 lower) lower)	Dery low	There is very low quality evidence that preopera- tive nebulized detomidine compared is effective in reducing Sh response to endotra- cheal intuba-
												tion at 1 min.

Table 2 (continued)

							Nº of patients		Effect		Certainty	Certainty Importance
Nº of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	dexmedetomidine nebulization	placebo or no intervention	Relative (95% Cl)	Absolute (95% CI)		
SBP at 2 min	SBP at 2 min (assessed with: mmHg)	nmHg)										
4	randomised Serious ^a trials		serious ^b	not serious	not serious	publication bias strongly suspected	55	165		MD 21 mmHg lower (30.41 lower to 11.6 lower)	Very low	There is very low quality evidence that preopera- tive nebulized dexme- detomialine compared in reducing SBP response to endotra- cheal intuba- tion at 2 min.
SBP at 5 min	SBP at 5 min (assessed with: mmHg)	nmHg)										
Ś	randomised Serious ^a trials		serious ^b	not serious	not serious	publication bias strongly suspected	200	200		MD 9.25 mmHg lower (14.99 lower to 3.51 lower)	dery low	There is very low quality evidence that preopera- tive nebulized dexme- detomiatine compared is effective in reducing SBP response to endotra- cheal intuba- tion at 5 min.

Table 2 (continued)

^a Multiple biases at individual study level ^b High heterogeneity and variability in effect estimates Cl Confidence interval, MD Mean difference

10, 14, 27, 28]. De Cassai et al. in a recent SRMA of 99 RCTs involving 6833 patients found significant bradycardia in one out of every 12 patients [4]. Nebulized dexmedetomidine provides an alternative route and was found to be devoid of these intra-operative adverse effects in this SRMA. Our findings corroborate with similar findings by other authors [14]. The heart rate safety profile of nebulized versus IV dexmedetomidine might be advantageous in patients with low baseline HR such as those on pre-operative beta-blocker therapy [13, 14]. Also, nebulized dexmedetomidine causes less postoperative sedation than IV dexmedetomidine which may be beneficial in resource-poor settings with inadequate postoperative monitoring facilities and in patients with obstructive sleep apnoea or chronic obstructive pulmonary disease in whom postoperative sedation might be detrimental [14].

Other potential benefits of nebulized dexmedetomidine, as observed in included studies in this SRMA, involved reduction in the induction dose of propofol, intraoperative requirement of opioids and halogenated anaesthetics and incidence of postoperative sore-throat. However, low number of studies precluded meta-analysis of these outcome. Some of these advantages might be attributed to sedative and analgesic action of dexmedetomidine by virtue of its α 2-agonistic action on the locus coeruleus [3]. Its dose-sparing effect on opioid and anaesthetic requirements have been shown to be comparable with intravenous dexmedetomidine [14]. Its short half-life and elimination life and easy acceptability in addition to its ability to provide a calm and sedated patient at induction, lower anaesthetic and analgesic requirements and devoid of adverse effects make nebulized dexmedetomidine an ideal premedication agent [13, 29]. The sedative action of nebulized dexmedetomidine is particularly advantageous in pediatric patients in whom it has been shown to reduce separation anxiety, recovery time, postoperative agitation, postoperative nausea and vomiting and improve mask acceptance; with nebulized dexmedetomidine shown to be better compared with nebulized ketamine and midazolam [3, 29, 30]. Another recent systematic review of 10 RCTs including 1233 patients established sedative efficacy of nebulized dexmedetomidine in pediatric patients undergoing medical examination or surgery [3]. Nebulized dexmedetomidine has been shown to ease and improve acceptability of IV cannulation; difficult in pediatric population owing to small veins and physical agitation [8, 31-33]. Postoperative sore throat is a common adverse effect after laryngoscopy and ETI and is associated with patient discomfort and dis-satisfaction after GA [34]. Congruent with our findings, others have also shown nebulized dexmedetomidine to reduce postoperative sore throat, better than that of IV dexmedetomidine [14]. This might be attributed to its anti-inflammatory action [14].

Sensitivity analysis by excluding study using a higher dose of nebulized dexmedetomidine (2 μ g/kg) did not reveal any major impact on the pooled effect estimate, suggesting against a dose-response effect. However, only one of the included RCT used a higher dose of dexmedetomidine precluding any conclusion on the dose-response effect of nebulized dexmedetomidine on the hemodynamic stress response. This warrants future studies comparing different doses of dexmedetomidine to confirm or refute any dose-response effect.

Limitations and strengths

This SRMA had few limitations. Exclusion of grey literature search and non-English studies might have led to missing out relevant articles. However, a comprehensive search of six (both uni-and multi-disciplinary) most relevant databases including google scholar (cataloguing both academic and grey literature) along with reference list and citation tracking were adopted to ensure that SR findings are informed by the best available evidence on the topic.

Secondly, only one-third of the included studies were at low risk of bias which reduced our certainty in the strength of evidence. This not only enable readers to view the available evidence in light of its quality but also provides useful insights for future triallists to improve the design and conduct of future RCTs to reduce the risk of biases identified in this SRMA.

Another limitation worth considering is the high heterogeneity observed in the effect estimates. A high I^2 value, for e.g. of 92% for HR at 1 min reflect that 92% of variance in the observed effect is due to variance in true effect and only 8% is due to variance in the sampling error. This was despite the study sample across the studies being quite homogenous with respect to the age, ASA physical status and surgeries as outlined in 3.2. Except for Hussain et al., all others used 1 μ g/kg as the dose of dexmedetomidine. A sensitivity analysis performed after excluding Hussain et al. in fact increased the heterogeneity for HR at 1 min (I^2 from 92 to 94%). The main source of clinical heterogeneity evident among the studies was the use of anti-emetics, anti-cholinergic and benzodiazepines as premedication, some of which (e.g. midazolam) have themselves been shown to attenuate hemodynamic response to ETI [35].

To the best of authors knowledge, this is the first SRMA to systematically and comprehensively evaluate efficacy and safety of dexmedetomidine nebulization for attenuating hemodynamic response to ETI. The strength of this SRMA lies in its transparent and rigorous methodology to identify, collate, appraise and synthesize the available evidence informing the review topic. Key review decisions were made in consultation with the Cochrane Handbook for Systematic Review of Interventions and the project advisory group comprising of both the subject and methodology experts [36]. Two independent reviewer with arbitration and audit process was adopted at screening, data extraction, meta-analysis, risk of bias and GRADE assessment.

Conclusions

Preoperative dexmedetomidine nebulization significantly reduces HR and BP response to laryngoscopy and ETI without any risk of adverse effects like bradycardia and hypotension. However, the strength of evidence is very low and warrants future properly designed and conducted RCTs to improve generalizability and strength of evidence. Future studies should also focus upon comparing different routes of dexmedetomidine administration and different doses of nebulized dexmedetomidine to establish a dose-response effect.

Abbreviations

BP	Blood Pressure
DBP	Diastolic blood pressure
ETI	Endotracheal intubation
HR	Heart Rate
HT	Hemanthkumar Tamilchelvan
MBP	Mean blood pressure
MG	Mayank Gupta
PRISMA	Preferred Reporting Items for Systematic reviews and
	Meta-analysis
PROSPERO	International Prospective Register of Systematic Reviews
RCT	Randomized Controlled Trial
RoB	Risk of Bias
SBP	Systolic blood pressure
SRMA	Systematic review and meta-analysis
UJ	Udita Joshi

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12871-023-02366-9.

Additional file 1: Supplementary Table I. Database Search Strategies. Supplementary file 2. Sensitivity analysis of Heart Rate. Supplementary file 3. Sensitivity analysis of Systolic Blood Pressure. Supplementary file 4. Funnel Plot of HR at 1 min.

Acknowledgements

None.

Authors' contributions

MG: Conceptualization, protocol registration, formulation of search strategy, database searches, record screening, data extraction, risk of bias assessment, data synthesis, grading strength of evidence, manuscript writing and editing. RR: Protocol registration, data extraction, risk of bias assessment, grading strength of recommendation, data synthesis, manuscript writing and editing. PG: Conceptualization, protocol registration, formulation of search strategy,

record screening, data extraction, risk of bias assessment, data synthesis, grading strength of evidence, manuscript writing and editing. HT: Conceptualization, record screening, data extraction, risk of bias assessment, grading strength of evidence, manuscript writing and editing. UJ: Formulation of search strategy, database searches, record screening, risk of bias assessment, grading strength of evidence, manuscript writing and editing. JK: Conceptualization, protocol registration, risk of bias assessment, manuscript writing and editing. All authors reviewed the manuscript.

Funding

None.

Availability of data and materials

All data generated or analysed during this study are included in this published article [and its supplementary information files].

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Anaesthesiology, All India Institute of Medical Sciences, Bathinda, Punjab, India. ²Department of Pharmacology, All India Institute of Medical Sciences, Bathinda, India. ³Department of Anaesthesiology, Graphic Era Institute of Medical Sciences, Dehradun, Uttarakhand, India. ⁴Banglore Hospice Trust, Bengaluru, Karnataka, India.

Received: 26 October 2023 Accepted: 30 November 2023 Published online: 11 December 2023

References

- Khan FA, Ullah H. Pharmacological agents for preventing morbidity associated with the haemodynamic response to tracheal intubation. Cochrane Database Syst Rev. 2013;(7):CD004087. https://doi.org/10.1002/ 14651858.CD004087.pub2.
- Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913. https://doi.org/10. 1007/s40262-017-0507-7.
- Lin J, Wu C, Zhao D, Du X, Zhang W, Fang J. The sedative effects of inhaled nebulized dexmedetomidine on children: a systematic review and metaanalysis. Front Pediatr. 2022;10:865107. https://doi.org/10.3389/fped.2022. 865107.
- De Cassai A, Boscolo A, Geraldini F, Zarantonello F, Pettenuzzo T, Pasin L, et al. Effect of dexmedetomidine on hemodynamic responses to tracheal intubation: a meta-analysis with meta-regression and trial sequential analysis. J Clin Anesth. 2021;72:110287. https://doi.org/10.1016/j.jclinane.2021.110287.
- Lu C, Zhang LM, Zhang Y, Ying Y, Li L, Xu L, et al. Intranasal dexmedetomidine as a sedative premedication for patients undergoing suspension laryngoscopy: a randomized double-blind study. PLoS One. 2016;11:e0154192.
- Niyogi S, Biswas A, Chakraborty I, Chakraborty S, Acharjee A. Attenuation of haemodynamic responses to laryngoscopy and endotracheal intubation with dexmedetomidine: a comparison between intravenous and intranasal route. Indian J Anaesth. 2019;63:915–23.
- Dogru K, Arik T, Yildiz K, Bicer C, Madenoglu H, Boyaci A. The effectiveness of intramuscular dexmedetomidine on hemodynamic responses during tracheal intubation and anesthesia induction of hypertensive patients: a randomized, double-blind, placebo-controlled study. Curr Ther Res Clin Exp. 2007;68:292–302.

- Zanaty OM, El Metainy SA. A comparative evaluation of nebulized dexmedetomidine, nebulized ketamine, and their combination as premedication for outpatient pediatric dental surgery. Anesth Analg. 2015;121(1):167–71.
- Li Z, Xu L, Zheng J, Wang Q. Comparison of intravenous dexmedetomidine versus esmolol for attenuation of hemodynamic response to tracheal intubation after rapid sequence induction: a systematic review and meta-analysis. Biomed Res Int. 2019;2019:6791971. https://doi.org/ 10.1155/2019/6791971.
- Mohsin S, Ahmad Ganaie Z, Kundi H, Ahmed MB, Riaz B, Khurshid Ahmed N, et al. Comparison of fentanyl and dexmedetomidine in preventing an increase in heart rate during intubation among patients undergoing general anesthesia: a meta-analysis. Cureus. 2022;14(6):e26194. https:// doi.org/10.7759/cureus.26194.
- Baumgartner K, Groff V, Yaeger LH, Fuller BM. The use of dexmedetomidine in the emergency department: a systematic review. Acad Emerg Med. 2023;30(3):196–208. https://doi.org/10.1111/acem.14636.
- Misra S, Behera BK, Mitra JK, Sahoo AK, Jena SS, Srinivasan A. Effect of preoperative dexmedetomidine nebulization on the hemodynamic response to laryngoscopy and intubation: a randomized control trial. Korean J Anesthesiol. 2021;74(2):150–7. https://doi.org/10.4097/kja.20153.
- Kumar NRR, Jonnavithula N, Padhy S, Sanapala V, Naik VV. Evaluation of nebulised dexmedetomidine in blunting haemodynamic response to intubation: a prospective randomised study. Indian J Anaesth. 2020;64(10):874–9. https://doi.org/10.4103/ija.IJA_235_20.
- Singh V, Pahade A, Mowar A. Comparison of intravenous versus nebulized dexmedetomidine for laryngoscopy and intubation-induced sympathoadrenal stress response attenuation. Anesth Pain Med. 2022;12(5):e132607. https://doi.org/10.5812/aapm-132607.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.
- Hussain M, Arun N, Kumar S, Kumar A, Kumar R, Shekhar S. Effect of dexmedetomidine nebulization on attenuation of hemodynamic responses to laryngoscopy. Randomized controlled study. Indian J Anesth Analg. 2019;6(4):1235–40.
- Sheth PA, Hathiwala H, Shah D. Effect of dexmedetomidine by nebulizer for blunting stress response to direct laryngoscopy and intubation. IJMA. 2021;4(4):76–80.
- Suryawanshi C, Ravindran RG, Sathvika P, Jawale R. Efficacy of preoperative dexmedetomidine nebulization on blunting the hemodynamic response to laryngoscopy and intubation. J Pharm Negat Results. 2022;13(6):4196–205.
- Shrivastava P, Kumar M, Verma S, Sharma R, Kumar R, Ranjan R, et al. Evaluation of nebulised dexmedetomidine given pre-operatively to attenuate hemodynamic response to laryngoscopy and endotracheal intubation: a randomised control trial. Cureus. 2022;14(5):e25223. https://doi.org/10. 7759/cureus.
- Kaila D, Sharma S, Mehta N. Effect of pre-operative dexmedetomidine nebulisation on the hemodynamic response to laryngoscopy and intubation. Int J Life Sci Biotechnol Pharma Res. 2023;12(1):1–7.
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/ 10.1136/bmj.d5928.
- Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022;18:e1230. https://doi.org/10.1002/cl2. 1230. Accessed 10 Sept 2023.
- Shribman AJ, Smith G, Achola KJ. Cardiovascular and catecholamine response to laryngoscopy with and without tracheal intubation. Br J Anaesth. 1987;59:295–9.
- Grover N, Taneja R, Rashid Y, Shrivastava N. Nebulised fentanyl, dexmedetomidine and magnesium sulphate for attenuation of haemodynamic response to laryngoscopy and tracheal intubation: a double-blinded,

randomised comparative study. Indian J Anaesth. 2023;67(8):730–5. https://doi.org/10.4103/ija.ija_397_22.

- Jain K, Sethi SK, Harsha KN, et al. Efficacy of dexmedetomidine in attenuating pressor response to laryngoscopy and endotracheal intubation under bispectral index controlled anesthesia: a prospective randomized double-blinded study. Ain-Shams J Anesthesiol. 2023;15:15. https://doi. org/10.1186/s42077-023-00314-w.
- Zhao W, Li J, Wang N, Wang Z, Zhang M, Zhang H, et al. Effect of dexmedetomidine on postoperative nausea and vomiting in patients under general anaesthesia: an updated meta-analysis of randomised controlled trials. BMJ Open. 2023;13(8):e067102. https://doi.org/10.1136/bmjop en-2022-067102.
- Bharati S, Pal A, Biswas C, Biswas R. Incidence of cardiac arrest increases with the indiscriminate use of dexmedetomidine: a case series and review of published case reports. Acta Anaesthesiol. 2011;49:165–7.
- Abdel-Ghaffar HS, Kamal SM, El Sherif FA, Mohamed SA. Comparison of nebulised dexmedetomidine, ketamine, or midazolam for premedication in preschool children undergoing bone marrow biopsy. Br J Anesth. 2018;121:445–52.
- Shereef KM, Chaitali B, Swapnadeep S, Gauri M. Role of nebulised dexmedetomidine, midazolam or ketamine as premedication in preschool children undergoing general anaesthesia-a prospective, double-blind, randomised study. Indian J Anaesth. 2022;66(Suppl 4):S200–6. https://doi. org/10.4103/ija.ija_931_21.
- Ali RM, Mahmoud NM. The effect of nebulized dexmedetomidine as sedative premedication in pediatrics undergoing cochlear implantation. Egypt J Anaesth. 2022;38(1):317–23.
- 32. Bonagua DM, Crisostomo HC, Hernandez AGC, Brodit SE. The effect of dexmedetomidine nebulization as a premedication prior to peripheral intravenous access in pediatric patients and its effect on separation anxiety score and acceptance to intrave-nous cannulation score. Pediatr Anesth Crit Care J. 2020;8(2):120–8.
- Çelikol Ş, TuralBüyük E, Yıldızlar O. Children's pain, fear, and anxiety during invasive procedures. Nurs Sci Q. 2019;32(3):226–32.
- Aqil M, Khan MU, Mansoor S, Mansoor S, Khokhar RS, Narejo AS. Incidence and severity of postoperative sore throat: a randomized comparison of Glidescope with Macintosh laryngoscope. BMC Anesthesiol. 2017;17(1):127. https://doi.org/10.1186/s12871-017-0421-4.
- 35. López Soriano F, Rivas López FA, Crespo Toral J, López Robles J, de la Rubia MA, Azurmendi Rodríguez JI, et al. Respuesta cardiovascular a la intubación orotraqueal utilizando midazolam o etomidato en la inducción anestésica [Cardiovascular response to orotracheal intubation using midazolam or etomidate in anesthesia induction]. Rev Esp Anestesiol Reanim. 1991;38(3):170–2.
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane; 2023. Available from www.training. cochrane.org/handbook.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

